þÿ

International Myeloma Foundation
Concise Review
of the Disease and Treatment Options
çúêëéÓÇÃ
ïaë`
Çé°ó
ÇÃÇÇÁÇ<Çµ
2003 Edition
íòÅFBrian G. M. Durie, M. D.
ñ|ñÛÅFíÜìcóTéq
äñÛÅFî®Å@óTîV

ñ/Å@éü
1

çúêëéÓçñEÇ...ÇÊÇÈíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÃéYê
çúêëéÓçñEÇÃì¡í·ÇÕÅAíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇéYêÇµååíÜÇ,îAíÜÇ...ïèoÇÇÈÇ±Ç
ÇÇÅBíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÕÅAÇlÉ^ÉìÉpÉNÅAçúêëéÓÉ^ÉìÉpÉNÅAÉpÉâÉvÉçÉeÉCÉìÇ
ÇÈÇ¢ÇÕÉXÉpÉCÉNÅEÉ^ÉìÉpÉNÇÇåÇOEÇÍÇ<ÇÅBíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇTMÅuÉXÉpÉCÉNÅv
ÇåÇOEÇÍÇÈÇÃÇÕÅAÉ^ÉìÉpÉNìdãCâjìÆñ@Ç...ÇÊÇÈÉ^ÉìÉpÉNïTMâÊÇ...Ç®Ç¢ÇâsäpÇÃïÙÅiÉXÉp
ÉCÉNîgå`ÅjÇÇµÇåªÇÍÇÈÇ±ÇÇ...óRóàÇµÇ<ÇÅB
Åiê}ÇQÅj
ÇlÉ^ÉìÉpÉNÇçÏÇ¡ÇÇ¢ÇÈçúêëéÓçñE
ê}ÇQÅFíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÃÅuÉXÉpÉCÉNÅv
â¬ïoeïî
åyç
ïsïoeïî
èdç
çRå¥åãçáïîïTM
Fab
ÇrÅ|Çr
åãçá
ÇøÇÂÇ§Ç¬ÇTMÇ¢ïîïTM
ï,ëÃåãçáïî
êï®äwìIì¡ê´åàíËïî
Fc
FcÉåÉZÉvÉ^Å[
åãçáïî
ê}ÇRÅFñâuÉOÉçÉuÉäÉìïTMéqç\ë¢
íPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÇÕñâuÉOÉçÉuÉäÉìÇÇÈÇ¢ÇÕÇªÇÃç\ê¨ê¨ïTMÇéwÇµÇ<ÇÅBê}3
ÇÕêèÌÇ»ñâuÉOÉçÉuÉäÉìÇÃïTMéqç\ë¢Çï\ÇµÇÇÇÃÇÇÅBçúêëéÓçñEÇ...Ç®Ç¢ÇÇÕñâu
ÉOÉçÉuÉäÉìÇÃéYêÇíSÇ§à,ì`éqÇ...àÍÇ¬à»è,,ÇÃïoeàYÇTMå©ÇÁÇÍÇ<ÇÅBÇªÇÃÇÇflçúêëéÓÉ^
ÉìÉpÉNÇÕàYèÌÇ»ÉAÉ~Émé_îzóÒÇÉ^ÉìÉpÉNç\ë¢ÇóLÇµÇ<ÇÅBàÍî Ç...êèÌÇ»ñâuÉOÉçÉu
ÉäÉìÇÃçRëÃã@î\ÇÕëÇ»ÇÌÇÍÅAïTMéqÇÃéOéüåç\ë¢ÇïoeâªÇµÇ<ÇÅBïTMéqç\ë¢Çã@î\ÇÃàY
2
3

1844-1850:çúêëéÓÇÃçèâÇÃè«ó·ÇÕÅuìÓê´ÇÇÇÎÇ¢çúÇÃèÛë`ÅvÇãLò^ÇÇÍÇÇ¢ÇÈÅBç
èâÇÃäé"ÇÇÇÍÇÈThomas Alexander
1 McBeanÇÕ
845
îNÉçÉìÉhÉìÇÃÉnÅ[Éå
Å[äXÇÃà,,ét
William MacintyreÇÃêfífÇéÛÇØÇÈÅBîAÇÃàYèÌÇÕDr. Henry
Bence JonesÇ...ÇÊÇ¡ÇêçÇÇÍÅAÇªÇÃåãâ
1848
ÇÕ
îNÇ...îï\ÇÇÍÇÈÅB
1846
îNÅAäOâ»à,,ÇÇÇÈ
John DalrympleÇÕçúÇÃïaïoeïîÇ...ì¡àYìIÇ»çñEÅiå,,Ç...å`
éøçñEÇÇÌÇ©ÇÈÅjÇÃëç>ÇîFÇflÇÇîï\ÇÇÈÅB
1850
îNÅA
Macintyre
ÇTMÉx
ÉìÉXÉWÉáÅ[ÉìÉYå^çúêëéÓÇÃè/çÇ»ÉfÅ[É^Çîï\ÇÇÈÅB
1844
îN Samuel
Solly Ç...ÇÊÇÈçúêëéÓÇÃè«ó·ïÒçêÅiSarah NewburyÅjÇTMíçñ/ÇèWÇflÇÈÅB
1873:
RustizkyÇTMçúÇÃëîê´å`éøçñEéæäÇÅuëîê´çúêëéÓÅvÇï\ÇÅB
1889:
Otto KahlerÇTMÅgKahlerïaÅh
Åiëîê´çúêëéÓÅjÇÃè/çÇ»ó'èëúÇîï\ÇÇÈÅB
1890:
Ramon Y Cajal ÇTMå`éøçñEÇÃåî~ãæëúÇîï\ÇÇÈÅB
1900:
WrightÇÕçúêëéÓçñEÇTMå`éøçñEÇ...óRóàÇÇÈÇ±ÇÇîå©ÇÇÈÅB
1903:
WeberÇÕXê¸ëúÇé¶ÇÇÍÇçúêëéÓÇÃçúéæäÅiónâê´çúïaïoeÅjÇ...íÖñ/ÇÇÈÅB
1909:
WeberÇ...ÇÊÇËçúêëÇÃå`éøçñEÇTMçúîjâÛÇà¯Ç´ãNÇ±ÇÇ±ÇÇTMé¶ç¥ÇÇÍÇÈÅB
1930îNë,,:çúêëêéhÇ...ÇÊÇÈåüçñ@ÇTMàÍî Ç...çLÇ<ÇÈÇ<ÇÇÕÅAçúêëéÓÇÃêfífÇÕç¢ìÔÇÇ
Ç¡ÇÅBí¥âìêSïTMó£äÌÇååê¥ÅEîAíÜÉ^ÉìÉpÉNÇÃìdãCâjìÆÇÕÉXÉNÉäÅ[ÉjÉìÉO
Ç®ÇÊÇ--êfífãZèpÇÃå¸è,,ÇÇÇÇÁÇÅB
1953:
íPÉNÉçÅ[Éìê´çúêëéÓÉ^ÉìÉpÉNÇÃìØíËÇâ¬î\Ç...ÇÇÈñâuìdãCâjìÆñ@ÇTMì±ì¸
ÇÇÍÇÈÅB
ÅiÇªÇÃå,,ñâuåíËñ@ÇTMÇÊÇËêìxÇÃçÇÇ¢âêÕñ@ÇÇµÇì±ì¸ÇÇÍÇÈÅj
1956:
Korngold
Ç
Lipari
ÇÕÅAÉxÉìÉXÉWÉáÅ[ÉìÉYÅEÉ^ÉìÉpÉNÇÕÅAååê¥É^ÉìÉpÉNÇÃ
àYèÌÇìØólÇ...ÅAååê¥ÉKÉìÉ}ÉOÉçÉuÉäÉìÇä÷åWÇTMÇÇÈÇ±ÇÇ...íÖñ/ÇÇÈÅBîfi
ÇÁÇ...ÇøÇ»ÇÒÇåyçÇÃïTMófiÇÕÉJÉbÉpÅikÅjå^ÅAÉâÉÄÉ_ÅilÅjå^ÇåÇOEÇÍÇÈÇÊ
Ç§Ç...Ç»ÇÈÅB
1958:
ÉTÉãÉRÉäÉVÉìÇÃîå©ÅBÇ±ÇÍÇ...ÇÊÇËÉÅÉãÉtÉ@ÉâÉìÅiÉAÉãÉPÉâÉì
T M
ÅjÇTMäJî
ÇÇÍÅAèâÇflÇé°óÇTMâ¬î\Ç...Ç»ÇÈÅB
1961:
Waldenstrom
ÇÕíPÉNÉçÅ[Éìê´ÇëÉNÉçÅ[Éìê´ñâuÉOÉçÉuÉäÉìååè«ÇÃà·Ç¢
ÇèdéãÇµÅA
IgMíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÉ}ÉNÉçÉOÉçÉuÉäÉìååè«Çä÷òAït
ÇØÅAçúêëéÓÇÃïTMófiÇ©ÇÁèúäOÇÇÈÅB
1962:
BergsagelÇ...ÇÊÇËÉÅÉãÉtÉ@ÉâÉììäó^Ç...ÇÊÇÈê¨å~ó·ÇTMèâÇflÇïÒçêÇÇÍÇÈÅB
1964:
Korst
Ç...ÇÊÇËÉVÉNÉçÉzÉXÉtÉ@É~ÉhÅiÉGÉìÉhÉLÉTÉì
T M
ÅjÇ...ÇÊÇÈé°óê¨å~ó·ÇTM
èâÇflÇïÒçêÇÇÍÇÈÅBÉVÉNÉçÉzÉXÉtÉ@É~ÉhÇÃé°óå¯â ÇÕÉÅÉãÉtÉ@ÉâÉìÇìØ
ìôÇÇÇÈÇ±ÇÇTMé¶ÇÇÍÇÈÅB
1969:
Alexanian
Ç...ÇÊÇÈÉÅÉãÉtÉ@ÉâÉìÇÉvÉåÉhÉjÉ]ÉìÇÃïópÇÕÉÅÉãÉtÉ@ÉâÉìíPç<
ÇÊÇËóLå¯ÇÇÇÈÇ±ÇÇTMé¶ÇÇÍÇÈÅB
1975:
Durie/Salmon
ÇÃïaäïTMófiÇTMîï\ÇÇÍÇÈÅBïaäÇ...ÇÊÇÈâªäwóñ@ÇÃÉxÉlÉtÉB
4
5

Åié©âÅjà/êAÇÃåüì¢ÇTMçsÇÌÇÍÇÇTMÅAè,,èÊÇå¯â ÇÃóLå¯ê´ÇÕé¶ÇÇÍÇ»Ç©Ç¡
ÇÅBíäÇÃí«ê'íçÇTMçsÇÌÇÍÇåãâ ÅAÇQîNä`ÇÃÉAÉåÉfÉBÉAÇÃìäó^ÇÕóLóp
è]óàÇÃïTMófi
èCêå,,ÇÃïTMófi
íËã`
ÇÇÇ¡ÇÇ±ÇÇTMé¶ÇÇÍÇÈÅBé©âà/êAå,,ÇÃäâÇÃÇÇÁÇ»ÇÈâ¸ëPÇñ/éwÇµÅA
ÉzÉãÉ~ÉEÉÄÇTMçúÇÃïéÀê¸é°óñÚÇÇµÇì±ì¸ÇÇÍÇÈÅB
MGUS
Åió«ê´íPÉNÉçÅ[
MGUSÇ<ÇÇÕ
ÅEíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇTMîFÇfl
Éìê´ñâuÉOÉçÉuÉäÉìåå
M G
ÅiíPÉNÉçÅ[Éìê´çÇ
2000:
óLñ]Ç»é°óÉAÉvÉçÅ[É`ÇTMêVÇÇ...ìoèÍÇÇÈÅBó'èééå±Çåüì¢ÇÇÍÇÇ¢ÇÈêV
ÇÁÇÍÇÈ
è«Åj
ÉKÉìÉ}ÉOÉçÉuÉäÉìååè«Åj
ÅEå¥ïaÇ...ä÷òAÇÇÈè«èÛÇÕîÇÌÇ»
ÇµÇ¢é°óñÚÇÕÅAÉTÉäÉhÉ}ÉCÉhófiéóëÃÅiè§ïiñºÅF
Selcid
ÅA
Imids
Åj
ÅAíéûä`
Ç¢
çÏópå^ÇÃÉAÉhÉäÉAÉ}ÉCÉVÉìófiéóëÃÅi
Doxil
Åj
ÅAéOé_âª·ÂëfÅi
ATO
Åj
ÅAååä«
êVêëjäQñÚÅiVEGF É`ÉçÉVÉìÉLÉiÅ[É[ëjäQñÚÅj
ÅAçñEê/íÖëjäQñÚÅA
Beta-
ÇÇÇ`ÇËå^çúêëéÓñè«åÛê´çúêëéÓ
MGUS
ÇófiéóÇÇÈÇTMÅAÇlê¨ïTMÇÃ
alethinÅiBeta-LTÅj
ÅAÉvÉçÉeÉAÉ\Å[ÉÄëjäQñÚÅiVelcadeTMÅjÇÇÇÈÅB
è,,è
2001:
çúêëéÓÇ®ÇÊÇ--çúêëéÓÇ...ä÷òAÇµÇéæïaÇÃêVÇÇ»ïTMófiëÃånÇTMíÒé¶ÇÇÍÇÈÅiï\
Ç<ÇÇÕèâäÇÃçúè«èÛÇTMîFÇflÇÁÇÍ
ÇÈ
ÇPéQèÅj
ÅBÇÇÁÇ...êVÇÇ»ó\å,,à^éqÅAïaäïTMófiÇTMîï\ÇÇÍÇÈÅB
SWOG ÅiSouthwest Oncology GroupÅj
ÇÕååê¥É¿
2É~ÉNÉçÉOÉçÉuÉäÉìÇåå
çúêëéÓ
Åiè«èÛÇÃÇÇÈÅjçúêëéÓ
ÅEíPÉNÉçÅ[Éìê´É^ÉìÉpÉN
ê¥ÉAÉãÉuÉ~ÉìílÇäÓÇ...élåQÇ...ïTMófiÇµÇÅB
ÅEëüäÌÇÃã@î\è·äQ*ÇTMîFÇflÇÁÇÍ
àÍï°ÅAIFM ÅiÉtÉâÉìÉXÇÃå§ãÜÉOÉãÅ[ÉvÅjÇÕååê¥É¿
2É~ÉNÉçÉOÉçÉuÉäÉìÇ
ÇÈ
FISHñ@Ç...ÇÊÇÈ13î`êiêFëÃÇÃåáëÇÃóLñÇäÓÇ...éOåQÇ...ïTMófiÇµÇÅB
2002:
VelcadeTM
ÅiÉ~ÉåÉjÉAÉÄéÇ...ÇÊÇÈëÊ
IIIëäééå±Åj
ÅA
Revimid
T M
ÅiÉZÉãÉWÅ[Éì
*CRABïTMófiÇ...ÇÊÇÈã@î\è·äQ
C: ÉJÉãÉVÉEÉÄílÇÃè,,èÅi>10mg/LÅj
éÇ...ÇÊÇÈëÊIIIëäééå±ÅjÇ»Ç«ÇÃêVãKñÚç<ÇÃóLå¯ê´ÇTMîFÇflÇÁÇÍÇÈÅB
R: êtè·äQÅiÉNÉåÉAÉ`ÉjÉìíl>2mg/dLÅj
ÉTÉäÉhÉ}ÉCÉhÇÉfÉLÉTÉÅÉ^É]ÉìÇÃïópÇ...Ç®Ç¢ÇñÒ
70ÅìÇÃëtå¯ó¶ÇTMìæÇÁÇÍ
A: ïnååÅiÉwÉÇÉOÉçÉrÉìíl<10gm/dLÅj
ÇÈÅBâpçë
MRC
ÇÕ
ASH
Ç...Çé©âà/êAÇ...ä÷ÇÇÈîï\ÇçsÇ§ÅBì¡Ç...É¿
2É~ÉNÉç
B: çúè«èÛÅióZâê´çúè«èÛÇ<ÇÇÕçúëeÇµÇÂÇ§è«Åj
ÉOÉçÉuÉäÉìÇTMçÇílÅi
>7.5
iÊ/dLÅjÇÇÇÈèÍçáÅAëççáìIÇ»óLå¯ê´ÇTMìæÇÁÇÍ
ÇÇåæãyÇµÇÅB
2003 B.J.Haematol.
2003:
ÉAÉÅÉäÉJÇÃà/êAå§ãÜÉOÉãÅ[ÉvÇ...ÇÊÇÈí èÌÇÃâªäwóñ@Çà/êAóñ@ÇîärÇµ
ÇëÂãKñÕÇ»å§ãÜÇÃåãâ ÇTMäë"ÇÇÍÇÈÅB
çúêëéÓÇÃâuäw
ÉAÉÅÉäÉJÇÇÕ
10ñúêlÇ...Ç¬Ç´ÇRÅ`ÇSêlÇTMçúêëéÓÇîè«ÇµÅAÇªÇÃîè«ó¶ÇÕÇTMÇÒëSëÃÇÃ
ñÒÇPÅìÇ...ëäìñÇµÇ<ÇÅBñàîNÇ®ÇÊÇª
14,500
êlÇTMêVÇÇ...çúêëéÓÇêfífÇÇÍÇ<ÇÅBÉAÉtÉä
ÉJånÉAÉÅÉäÉJêlÇÕîíêlÇÊÇËîè«ó¶ÇTMçÇÇÅAÉçÉTÉìÉ[ÉãÉXÇ...Ç®ÇØÇÈîè«ó¶Çó·Ç...ãìÇ
ÇÈÇÅAÉAÉtÉäÉJånÉAÉÅÉäÉJêlíjê´ÇÃèÍçáÇÕ
10ñúêlíÜ9.8êlÇÇÇTMÅAîíêlíjê´ÇÇÕ
10ñú
êlíÜ4.3êlÇTMçúêëéÓÇîè«ÇµÇÇ¢ÇÈÇ±ÇÇ...Ç»ÇËÇ<ÇÅBîè«ó¶ÇÕçëÇ...ÇÊÇ¡ÇàYÇ»ÇËÅAíÜ
çëÇÇÕ
10ñúêlìñÇÇË1êlÇTMîè«ÇµÇÇ¢Ç<ÇÇTMÅAêºë§êÊêièîçëÇÇÕñÒÇSêlÇÇÅBíjèóî
ÇÕÇRÅFÇQÇÅAíjê´ÇÃï°ÇTMëÇÇ>ÇÁÇÍÇ<ÇÅBîNóÓÇ...ÇµÇÇTMÇ¡Çîè«ó¶Çè,,èÇµÇ<ÇÅB
êîè\îNëOÇ...îÇîè«ó¶ÇTMè,,èÇµÇÇ¢ÇÈÇÃÇÕÅAêfífãZèpÇÃå¸è,,ÇçÇóÓâªÇÃâeãøÇÇÇÈ
Ç©ÇÇµÇÍÇ<ÇÇÒÅB
55çOEñ¢ñûÇÃäé"ÇTMëùâ¡åXå¸Ç...ÇÇÈÇ±ÇÇÕÅAâflãé
60îNÇÃä¬ã´ÇÃïoeâª
ÇTMèdóvÇ»ÉtÉ@ÉNÉ^Å[ÇÇÇÈÇ±ÇÇé¶ç¥ÇµÇÇ¢Ç<ÇÅB
6
7

10
ñè«åÛä
è«åÛä
äàìÆê´ÇÃÇÇÈ
çúêëéÓ
MGUSÇ<ÇÇÕ
çî
ìÔé°ê´ÇÃçî
5
ñè«åÛê´
ÅiÇÇÇ`ÇËå^Åj
çúêëéÓ
ÉvÉâÉgÅ[ä
2
é°ó
éûä`
ê}ÇSÅFçúêëéÓÇÃåoâfl
é°óÇ...ÇÊÇ¡ÇñÒ
75ÅìÇÃäé"ÇTMâÇÁÇ©ÇÃó'èìIÇ»â¸ëPÇìæÇÇ¢Ç<ÇÅBì¡ïMÇÇÇ´ÇÕÅA
äâÇçîÅiÇ<ÇÇÕçîRÅjÇâìxÇåJÇËï`ÇÇ±ÇÇTMÇÇËìæÇÈÇ±ÇÇÇÅBçúêëéÓÇÃåo
âflÇÃëSëÃëúÇÕê}ÇSÇ...é¶ÇµÇí ÇËÇÇÅBïaë`êóùäwÇ...Ç¬Ç¢ÇÇÕï\ÇQÇ...äTóvÇÇ<ÇÇflÇ
Ç¢Ç<ÇÅB
ï\ÇQÅ@çúêëéÓÇÃïaë`êóùäwÅ|äTóv
çúÇÃèÛë`
ÅEíPìÇ<ÇÇÕï°êîÇÃónâê´çúïaïoeÇTMîFÇflÇÁÇÍÇÈ
ÅEçLîÕÇ»çúëeÇµÇÂÇ§è«Åiçúó ÇÃåèÅjÇTMîFÇflÇÁÇÍÇÈ
çúîjâÛÇ...ÇÊÇÈêèîè«èÛ
ÅEååê¥ÉJÉãÉVÉEÉÄílÇÃè,,è
ÅEçÇÉJÉãÉVÉEÉÄîAè«ÅiîAíÜÉJÉãÉVÉEÉÄílÇÃè,,èÅj
ÅEêgíÇÃí·âÅiíçúÇÃàîóçúê<Ç...ÇÊÇÈÅj
êëäOê´å`éøçñEéÓ ìÓïîëgêDÇ÷ÇÃêZèÅÅAàÍî Ç...ÇÕìTMËÚïîÅiè,,àÙìTMÅjÇTMëÇÅAäÃëüÅA
êtëüÅAÇªÇÃÇYÇ©ÇÃìÓïîëgêDÇ...ÇâeãøÇãyÇ/Ç
ññèåå
ÅEïnååÅ@ÅEãåàYèÌÅ@ÅEîíååãÖåèÅ@ÅEååè¨î¬åè
ÅEå`éøçñEê´îíååïaÅ@
ÅEíPÉNÉçÅ[Éìê´BçñEÉäÉìÉpãÖÇÃëùâ¡ÅiçúêëéÓçñEÇÃëOãÏëÃÅj
ååü~É^ÉìÉpÉNÇÃàYèÌ
ÅEçÇÉ^ÉìÉpÉNååè«ÅiÉ^ÉìÉpÉNÇÃè,,èÅj
ÅEëååÅiååâtó ÇÃëùâ¡Åj
ÅEíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÃëùâ¡
ÅiIgGÅAIgDÅAIgAÅAIgMÅAIgDÅAåyçÅj
ÅEÉAÉjÉIÉìÉMÉÉÉbÉvÇÃí·âÅiååê¥ÉiÉgÉäÉEÉÄÇÃí·âÅj
ÅEååê¥É¿
2É~ÉNÉçÉOÉçÉuÉäÉìílÇÃè,,è
ÅEååê¥ÉAÉãÉuÉ~ÉìílÇÃí·â
ÅEååê¥IL6ÇCRPÇÃè,,è
êtè·äQ
ÅEÉ^ÉìÉpÉNîAÅAîíååãÖãyÇ--ê`ååãÖÇä<Ç<Ç»Ç¢â~íå
ÅEÉAÉVÉhÅ[ÉVÉXÇîÇ§îAçä«àYèÌ
ÅEîAìè«ÅiêtïsëSÅj
ÅEÉAÉ~ÉçÉCÉhÅ[ÉVÉX
8
9

É@ÉìÉRÅ[Éjè«åÛåQÇÇÕÅAêtîAçä«ã@î\ÇÃì¡í·ìIÇ»è·äQÇîÇ§àÍòAÇÃè«èÛÇéwÇµÅAîA
íÜÇ...ÉAÉ~Émé_Ç,ÉäÉìé_âñÇîrüïÇµÅAçúë,,é"è·äQÇà¯Ç´ãNÇ±ÇµÇ<ÇÅBÉJÉãÉVÉEÉÄÇ,îA
é_ÇÃëùâ¡ÅAä¥êiÅAêtìê´ÇÃÇÇÈçRêï®éøÅAîÒÉXÉeÉçÉCÉhê´çRâäè«ç<ÅAêfífåüçÇ...óp
Ç¢ÇÁÇÍÇÈë¢âeç<Ç,êFëfÇÕÅAÇÇÁÇ»ÇÈêtè·äQÇÇÇÇÁÇâ¬î\ê´ÇTMÇÇËÇ<ÇÅBÇ±ÇÍÇÁÇÃ
äÎåØà^éqÇ©ÇÁêtëüÇéÁÇÈÇÇflÇ...ÇÕÅAêÖïTMï,ããÇåpë±ÇµÇçsÇ§Ç±ÇÇTMÇÇÇëÂêÿÇÇÅB
ÇªÇÃÇYÇ©ÇÃëüäÌè·äQ
çúêëéÓçñEÇÕÅAçúêëÇ,ÇÇ<Ç¥Ç<Ç»ëgêDÇ...í~êoeÇµÅAçLîÕÇ...ÇÌÇÇÈçáïè«Çà¯Ç´ãNÇ±
ÇµÇ<ÇÅB
éÌÅ@ófi
Åì
åv
ê_åoè·äQ
çúêëéÓÉ^ÉìÉpÉNÇÃê_åoÅiÉ~ÉGÉäÉìè,Ç»Ç«ÅjÇ...ëOEÇÇÈíºê/ìIÇ»âeãøÇ,ÅAÉAÉ~ÉçÉCÉh
1. ååê¥É^ÉìÉpÉN
ÇÃíæíÖÇ...ÇÊÇÈã@î\è·äQÇ...ÇÊÇËÅAê_åoëgêDÇTMÇµÇOEÇµÇOEâeãøÇéÛÇØÇ<ÇÅBÇªÇÃÇÇflññè
IgG
52
ê_åoè·äQÇTMåªÇÍÇ<ÇÇTMÅAìúîAïaÇ»Ç«ÇYÇ©ÇÃå¥à^Ç...ÇÊÇÈê_åoè·äQÇãÊï ÇµÇ»ÇØÇÍÇOEÇ»
IgA
21
75Åì
IgD
2
ÇËÇ<ÇÇÒÅBä¥êiè«Ç...Ç©Ç©ÇËÇ,ÇÇ¢èÛë`ÇÇÇÈÇÇflÅAê_åoëgêDÇÃÉEÉCÉãÉXä¥êiÇTMÇµÇOE
IgE
<0.01
ÇµÇOEãNÇ±ÇËÅAÇÇËÇÌÇØë--èÛ·vê]Ç,ÉxÉãñÉ·ÉÅiÉEÉCÉãÉXä¥êiÇTMå¥à^ÇçlÇ¶ÇÁÇÍÇÈäÁñ
ãÿÇÃñÉ·ÉÅjÇTMàÍî ìIÇ...å©ÇÁÇÍÇ<ÇÅB
2. îAíÜÉ^ÉìÉpÉNÅiÉxÉìÉXÉWÉáÅ[ÉìÉYÇ<ÇÇÕåyçÅjÉ»Ç<ÇÇÕÉ...å^
11Åì
å`éøçñEéÓ
3. 2Ç¬à»è,,ÇÃíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇéYêÇÇÈ
<1
çúÇ®ÇÊÇ--ìÓïîëgêDÇ...îêÇµÅAê_åoÇ,ê"íÇÕÇÇÇÊÇËî]ëgêDÇ...Ç®Ç¢ÇÇàîóÇ,ïoeà
èdçÅiÉ¡Ç<ÇÇÕÉøçÅjå^
<1
2Åì
íPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÕîFÇflÇÁÇÍÇ»Ç¢
1
Çà¯Ç´ãNÇ±ÇµÇ<ÇÅBê_åoàîóÇÕãYã}è«èÛÇÃàÍÇ¬ÇÇÇËÅAçÇópó ÉRÉãÉ`ÉRÉXÉeÉçÉCÉh
ÇÃìäó^Ç,ïéÀê¸óñ@ÇíºÇøÇ...çsÇ§ïKóvÇTMÇÇËÇ<ÇÅB
4. IgMÅiÇÇèÇ»Ç¢ÅAí èÌÇÕå¥îê´É}ÉNÉçÉOÉçÉuÉäÉìååè«Ç...ä÷òAÅj
12Åì
ä¥êiè«
çáåvÅ@100Åì
ä¥êiÇµÇ,ÇÇ¢åXå¸ÇÕÅAçúïaïoeÇÃãNÇ±ÇåXå¸Çï¿ÇÒÇÅAçúêëéÓÇÃçÇì¡í·ìIÇ»è«èÛ
èoìTÅFPruzanski, OgryzioÇ...ÇÊÇÈ1,827è«ó·ÇÃïTMêÕÇ...äÓÇÇ
ÇÇÅBÇªÇÃîè«ÉÅÉJÉjÉYÉÄÇÕäÆëSÇ...ÇÕâñæÇÇÍÇÇ¢Ç<ÇÇÒÅBäàìÆê´ÇÃçúêëéÓÇÃèÍçáÅA
êèÌÇ»çRëÃÇÃéYêÇTMñWÇÇÁÇÍÅií·ÉKÉìÉ}ÉOÉçÉuÉäÉìååè«Åj
ÅAÇs-ÉäÉìÉpãÖÇÃã@î\è·äQÅA
íPãÖÅEÉ}ÉNÉçÉtÉ@Å[ÉWÇÃàYèÌÇTMãNÇ±ÇËÅAñâuã@î\ÇëjäQÇµÇ<ÇÅBÇ¢ÇÇ¬Ç©ÇÃå§ãÜåã
â ÇÕäàê´âªÇÇÍÇÉ}ÉNÉçÉtÉ@Å[ÉWÇTMçúêëéÓÇÃäàìÆê´Çò¥êiÇÇÈàÍï°ÅAêèÌÇ»ñâuÉO
ÉçÉuÉäÉìÇÃéYêó}êßÇ®ÇÊÇ--Çs-ÉäÉìÉpãÖÇÃã@î\ÇëjäQÇÇÈÇé¶ç¥ÇµÇÇ¢Ç<ÇÅB
çúêëéÓÇÃäé"ÇÕåóàÉEÉCÉãÉXê´îxâäÇ,îxâäãÖã¤Ç»Ç«ÇÃîÌïÔê´ÇÃçã¤ä¥êiÇãNÇ±Çµ
Ç,ÇÇ¢ÇÃÇÇÇTMÅAì¡Ç...é°óíÜÇÃäé"Ç...Ç®Ç¢ÇÇÕÅAçDíÜãÖåèÇ,ëÂó âªäwóñ@ÇÃâeãø
Ç...â¡Ç¶ÅAÉJÉeÅ[ÉeÉãÅiÉqÉbÉNÉ}ÉìÉJÉeÅ[ÉeÉãÇ»Ç«Åjë}ì¸ïîÇÃã«èää¥êiÇãNÇ±ÇËÇ,Ç
ÇÅAÇÇ<Ç¥Ç<Ç»çã¤Ç,ê^ã¤ÇÃä¥êiè«Ç®ÇÊÇ--ìòaå©ä¥êiè«Çà¯Ç´ãNÇ±Çâ¬î\ê´ÇTMÇÇË
Ç<ÇÅB
10
11

ó'èè«èÛ
çúêëéÓäé"ÇÃñÒ
70ÅìÇ...Ç®Ç¢Ç·uí...ÇTMîåªÇµÅAÇªÇÃí^ìxÇÕÇÇ<Ç¥Ç<ÇÇÇTMÅAÇµÇOEÇµ
ÇOEçòïîÇ,ò]çúÇ...í...Ç>ÇTMêÇÇ<ÇÅBìÀëRãNÇ±ÇÈèdìÇ»·uí...ÇÕê"íÇÃçúê<Ç,àîóÇÃí·åÛ
ÇÇÇÈÇ±ÇÇTMçlÇ¶ÇÁÇÍÇ<ÇÅB
ëÃíïsó«Ç,ïsíËèDëiÇÕÇµÇOEÇµÇOEå©ÇÁÇÍÇ<ÇÇTMÅAíòÇµÇ¢ëÃèdåèÇTMãNÇ±ÇÈÇ±ÇÇÕÇY
ÇÇÒÇ«ÇÇËÇ<ÇÇÒÅB
çDíÜãÖåèÇí·ÉKÉìÉ}ÉOÉçÉuÉäÉìååè«Ç...ÇÊÇËä¥êiè«ÇãNÇ±ÇµÇ,ÇÇÇ»ÇËÇ<ÇÅBîx
âäãÖã¤ê´îxâäÇÕçúêëéÓÇ...ä÷òAÇÇÈä¥êiè«ÇÃíÜÇÇÕìTå^ìIÇ»ÇÇÃÇÇÇTMÅAòAçãÖã¤Ç,
ÉuÉhÉEãÖã¤Ç»Ç«ÇÃçã¤ä¥êiÇÇµÇOEÇµÇOEå©ÇÁÇÍÇ<ÇÅBÉwÉÇÉEÉCÉãÉXëÆÇÃä¥êiè«Ç,ë--èÛ
·vê]ÇTMîåªÇÇÈÇ±ÇÇÇÇËÇ<ÇÅB
çÇÉJÉãÉVÉEÉÄååè«ÇÕçúêëéÓÇêfífÇÇÍÇéûì_ÇñÒ
30ÅìÇÃäé"Ç...îFÇflÇÁÇÍÅAåëë"ä¥ÅA
å°äâÅAà´êSÇ»Ç«ÇÃè«èÛÇà¯Ç´ãNÇ±ÇµÇ<ÇÅBÉJÉãÉVÉEÉÄâñÇÃíôóØÇÕêtã@î\Çí·âÇÇ
Ç<ÇÅBçúêëéÓÉ^ÉìÉpÉNÇÃëùâ¡ÇTMà¯Ç´ãNÇ±ÇâflîS,fÇÕÅAéáî¡ÅAï@èoååÅAéãäoàYèÌÅiÇ©
ÇÇ>ñ/Åj
ÅAìTMí...ÅAè¡âªä«èoååÅAñãCÅAê_åoëgêDÇ÷ÇÃååâtãüããÇÃåèÇ...ÇÊÇÈãïååê´ÇÃê_
åoè«èÛÇ»Ç«ÅAÇÇ<Ç¥Ç<Ç»è«èÛÇÇÇÇÁÇµÇ<ÇÅBâflîS,fÇTMÇ>ÇÁÇÍÇÈÇÃÇÕçúêëéÓäé"ÇÃ
10Åìñ¢ñûÇÇÇTMÅAå¥îê´É}ÉNÉçÉOÉçÉuÉäÉìååè«Åi
IgMå^É^ÉìÉpÉNÇ<ÇÇÕÇl-ê¨ïTMÇéY
êÇÇÈÅjÇÃäé"Ç...Ç®Ç¢ÇÇÕñÒîºêîÇTMâflîS,fÇÃâeãøÇéÛÇØÇ<ÇÅBèoåååXå¸ÇÕãåà^éq
Ç,ååè¨î¬ÇíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇTMåãçáÇÇÈÇ±ÇÇ...â¡Ç¶ÅAååè¨î¬åèÇ...ÇÊÇ¡ÇÇò¥
êiÇµÇ<ÇÅB
ê_åoè·äQÇÕïîà Ç...ÇÊÇ¡Çì¡óLÇÃè«èÛÇé¶ÇµÇ<ÇÅBê"êëàîóÅAêëñåâäÅAéËçTMä«è«åÛ
åQÇTMì¡Ç...ÇÊÇå©ÇÁÇÍÇÈÇÇÃÇÇÅBê"êëàîóÅAêëñåâäÇÕå`éøçñEÇÃéÓ·éå`ê¨ÇÇÈÇ¢ÇÕ
íôóØÇ...ÇÊÇÈÇÇÃÇÇÇTMÅAéËçTMä«è«åÛåQÇÕí èÌÉAÉ~ÉçÉCÉhÇÃíæíÖÇ...ÇÊÇ¡ÇãNÇ±ÇËÇ<Ç
ÅiÉxÉìÉXÉWÉáÅ[ÉìÉYÅEÉ^ÉìÉpÉNÇTMÉxÅ[É^ç\ë¢ÇÃå`ÇÇÇËëgêDÇ...íæíÖÇÇÈÅj
ÅB
ïaäïTMófiÇó\å,,à^éq
çúêëéÓÇÃó\å,,ÇÕçúêëéÓçñEÇÃó Çì¡ê´Ç...ÇÊÇ¡ÇåàíËÇÇÍÇ<ÇÅBì¡ê´ÇÇµÇÇÕÅAëù
êBë¨ìxÅiïTMâÊÅj
ÅAíPÉNÉçÅ[Éìê´É^ÉìÉpÉNÇÃéYêë¨ìxÅAÉTÉCÉgÉJÉCÉìÇ,êëÃìï®éøÇÃéY
êÅEîÒéYêÇ»Ç«ÇTMÇÇËÅAÇ±ÇÍÇÁÇÃâeãøÇéÛÇØÇÇYÇ©ÇÃëgêDÅAëüäÌÅAêëÃã@î\ÇTMíòÇµ
Çè·äQÇÇÍÇ<ÇÅB
1975
îNÇ...
Durie
ÅïSalmon
ïaäïTMófiÇTMì±ì¸ÇÇÍÇ<ÇµÇÇTMÅAÇ±ÇÃïTMófi
ÇÕçúêëéÓçñEó ÅiëÃìÇÃçúêëéÓçñEÇÃêîÅjÇëää÷ÇÇÈéÂÇ»ó'èìIÉpÉâÉÅÅ[É^ÇëgÇ>
çáÇÌÇÇÇÇÃÇÇÅB
Åiï\ÇSÅj
12
13

ï\ÇSÅ@DurieÅïSalmon ïaäïTMófiñ@
îªíËäÓèÄ
çúêëéÓçñEêîÅi10â/m2Åj
ïaäÉXÉeÅ[ÉWI ÅiéÓ·áó ÅFèÇ»Ç¢Åj
âãLÇÃÇÇÇÇ...äYìñÇÇÈ
ÅEÉwÉÇÉOÉçÉrÉìíl>10gm/dL
ÅEååíÜÉJÉãÉVÉEÉÄîZìxÇTMêèÌÇ<ÇÇÕ<10.5mg/dL
ÅEçúXê¸ëúÇTMêèÌÅiscale 0ÅjÇ<ÇÇÕå«óßê´å`éøçñEéÓÇÃÇ>
600*
ÅEMê¨ïTMÇÃéYêÇTMèÇ»Ç¢
IgG<5.0gm/dL
IgA<3.0gm/dL
É^ÉìÉpÉNìdãCâjìÆÇ...ÇÊÇÈîAíÜÇÃMê¨ïTMåyç<4gm/24h
ïaäÉXÉeÅ[ÉWII ÅiéÓ·áó ÅFíÜí^ìxÅj
600Å`1,200*
ïaäIÇ...ÇIIIÇ...ÇäYìñÇµÇ»Ç¢ÇÇÃ
Complete Response ÅiCRÅj
ïWèÄìIÇ»íËã`*
ïaäÉXÉeÅ[ÉWIIIÅiéÓ·áó ÅFëÇ¢Åj
äÆëSäâ
7 5Åìà»è,,ÇÃååê¥MÉ^ÉìÉpÉNÇÃåèÇ<ÇÇÕ
âãLÇÃèÇ»ÇÇÇàÍÇ¬Ç...äYìñÇÇÈ
90Åìà»è,,ÇÃîAíÜÇlÉ^ÉìÉpÉNÇÃåè
ÅEÉwÉÇÉOÉçÉrÉìíl<8.5gm/dL
ÅEååíÜÉJÉãÉVÉEÉÄîZìx>12mg/dL
True Complete Response
äÆëSäâÇÃÇÊÇËåµñßÇ»íËã`
ÅEèdìxÇÃónâê´ÇÃçúïaïoeÇîFÇflÇÈÅiscale3Åj
>1,200*
ê^ÇÃäÆëSäâ
ñâuåíËñ@Ç...ÇÊÇËämîFÇÇÍÇååê¥Ç®ÇÊÇ--îAíÜ
ÅEMê¨ïTMÇÃéYêÇTMëÇ¢
ÇÃÇlÉ^ÉìÉpÉNÇÃè¡éÇ©Ç¬çúêëéÓçñEÇÃè¡é
IgG>7.0gm/dL
IgA>5.0gm/dL
Partial ResponseÅiPRÅj
50Åìà»è,,75Åìñ¢ñûÇÃÇlÉ^ÉìÉpÉNÇÃåè
É^ÉìÉpÉNìdãCâjìÆÇ...ÇÊÇÈîAíÜÇÃMê¨ïTMåyç>12gm/24h
* ëÃëSëÃÇÃçúêëéÓçñE
ïîïTMäâ
ÉTÉuïTMófi
ÅiAÇ<ÇÇÕBÅj
Objective Response ÅiORÅj
à¿íËïaë`
ÅEA: êtã@î\ÇÕêèÌÇÇÇÈ
ãÔåªäâ
25Åìà»è,,50Åìñ¢ñûÇÃÇlÉ^ÉìÉpÉNÇÃåè
ååê¥ÉNÉåÉAÉ`ÉjÉìíl<2.0mg/dL
No ResponseÅiNRÅj
25Åìñ¢ñûÇÃÇlÉ^ÉìÉpÉNÇÃåè
ÅEB: êtã@î\ÇÃí·âÇîFÇflÇÈ
ïsïoe
Ç<ÇÇÕ25Åìñ¢ñûÇÃëùëÂ
ååê¥ÉNÉåÉAÉ`ÉjÉìíl>=2.0mg/dL
Progressive Disease ÅiPDÅj
ï\ãLó·ÅF
25Åìà»è,,ÇÃÇlÉ^ÉìÉpÉNÇÃëùëÂ
êiçs
ïaäÉXÉeÅ[ÉWáTA ÅiéÓ·áó ÇTMèÇ»ÇÅAêtã@î\ÇTMêèÌÇ»èÍçáÅj
ïaäÉXÉeÅ[ÉWáVB ÅiéÓ·áó ÇTMëÇÅAêtã@î\ÇTMí·âÇµÇÇ¢ÇÈèÍçáÅj
*íîNÇ...ÇÌÇÇËSWOG (Southwest Oncology Group)Ç...ÇÊÇËégópÇÇÍÇÇ´ÇíËã`
14
15

ï\ÇUÅ@çúêëéÓÇÃé°óëIëéà
1. âªäwóñ@
2. à/êAÇîÇ§ëÂó âªäwóñ@
3. ïéÀê¸óñ@
4. à¤éùóñ@
5. éxéùóñ@
ÅEÉGÉäÉXÉçÉ|ÉGÉ`ÉìÅ@Å@Å@Å@Å@Å@Å@ÅE·uí...ä«óù
ÅEÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<Å@Å@Å@ÅEëùêBà^éq
ÅEçRêï®éøÅ@Å@Å@Å@Å@Å@Å@Å@Å@Å@Å@ÅEåíËëïãÔÅEÉRÉãÉZÉbÉg
ÅEêHâaóñ@Å@Å@Å@Å@Å@Å@Å@Å@Å@Å@Å@ÅEâ^ìÆ
ñÚç<ñº
è§ïiñºÇ»Ç«ÇÃï ñº ÉRÉÅÉìÉg
ÅEãYã}è«èÛÇÃÉPÉAÅió·ÅFìßêÕÅAååü~åäÅAéËèpÅj
6. é°óíÔçRê´çúêëéÓÇÃé°ó
ÉÅÉãÉtÉ@ÉâÉì*ÉAÉãÉPÉâÉì
TM
íPç<ÇÇµÇçÇóLå¯Ç»é°óñÚ
7. êVãKñÚç<Ç...ÇÊÇÈé°ó
ÅiMÅj**
Åiåoå°Ç<ÇÇÕêíçÅj
ÅEÉTÉäÉhÉ}ÉCÉhÇ®ÇÊÇ--ÉTÉäÉhÉ}ÉCÉhófiéóëÃ
Revimid
TM
/Actimid
TM
ÅEVelcade
TM
ÅiÉvÉçÉeÉAÉ\Å[ÉÄëjäQç<Åj
ÉVÉNÉçÉzÉXÉtÉ@É~Éh*
ÉGÉìÉhÉLÉTÉì
TM
MÇìØìôÇÃå¯â Çé¶ÇÇTMÅAè¡âªäÌÅAîÂîA
ÅEÉAÉhÉäÉAÉ}ÉCÉVÉìÇÃë,,ë÷ÇÃDoxil
TM
ÅiíäçÏópå^ÉAÉhÉäÉAÉ}ÉCÉVÉìÅj
ÅiCÇ<ÇÇÕCYÅj**
Åiåoå°Ç<ÇÇÕêíçÅjäÌìê´ÇÕÇÊÇËãÇ¢ÅBçúêëÇÃë¢ååäçñEÇ÷
ÅETrisenox
TM
ÅiéOé_âª·ÂëfÅjó'èééå±é¿é{íÜ
ÇÃâeãøÇÕÇÊÇËåyìxÇÇÇÈ
ÅEHolmium
TMçúÇïWìIÇÇÇÈïéÀê¸é°óñÚ
ÅEÉ~Éjà/êAÅiîÒçúêëîjâÛìIìØéÌà/êAÅj
BCNU
Å¶
Bis-chloro-Nitrosourea
TM
MÅACÇófiéóÇÇÈÇTMÅAå¯â ÇÕÇÊÇËí·ÇÅA
ÅiBÅj**
ÅiêíçÇÃÇ>Åj
ì¡Ç...çúêëÇîxÇ...ëOEÇÇÈìê´ÇTMãÇ¢
ÉvÉåÉhÉjÉ]Éì
Prednisolone
TM
íºê/çÏópÇµÅAMÅACÅABÇÇÃïópÇ...ÇÊÇË
é°ó
ÅiPÅj**
Åií èÌåoå°ìäó^Åj
å¯â ÇTMëùãÇÇÈÅBçúêëó}êßÇãNÇ±ÇÇ»Ç¢
çúêëéÓÇÃóéjÇÃèÕÇÅAåªç>égópÇÇÍÇÇ¢ÇÈé°óñ@ÇÃîìWÇÃåoà<ÇTMäTäoeÇÇ´Ç<ÇÅB
ÉfÉLÉTÉÅÉ^É]Éì
ÉfÉJÉhÉçÉì
TM
ÉvÉåÉhÉjÉ]ÉìÇófiéóÇÇÈÇTMÅAÇÊÇËå¯â ÇTM
ÅiDÅj**
Åiåoå°Ç<ÇÇÕêíçÅjçÇÇÅAïõçÏópÇãÇîåªÇÇÈ
1962
îNÉÅÉãÉtÉ@ÉâÉìÇ...ÇÊÇÈé°óÇTMèâÇflÇì±ì¸ÇÇÍÇà»óàÅAÇÇ<Ç¥Ç<Ç»ïópóñ@ÇTMéé
çsÇÇÍÅAÇÇÁÇ...ÇÕçúêëà/êAÅi
BMT
ÅjÇÇÈÇ¢ÇÕññèååë¢ååäçñEà/êAÅiPBSCT Ç<Ç
ÉrÉìÉNÉäÉXÉ`ÉìÉIÉìÉRÉrÉì
TM
çÏópÇÕÇªÇÍÇYÇ«ëÂÇ´ÇÇ»ÇÅAïópóñ@Ç
ÅiVÅj**
ÅiêíçÇÃÇ>Åj
ÇÕ
PSCT
ÅjÇîÇ§ëÂó âªäwóñ@Ç...ÇÊÇ¡Çé°óê¨â Çå¸è,,ÇÇÇÈééÇ>ÇTMçsÇÌÇÍÇ<ÇµÇÅB
égópÇÇÍÇÈ
ÅiVADÇ»Ç«Åj
ïWèÄìIÇ»
BMT
Ç,PBSCT
Ç...Ç®ÇØÇÈÅuà/êAÅvÇÇÕÅAëÂó âªäwóñ@Ç...ÇÊÇËë¢ååäçñEÇTMîj
âÛÇÇÍÇå,,Ç...ÅAêèÌÇ»çúêëÇÃë¢ååäçñEÇóAíçÇµÇÅuã~èïÅvÇÇÈÇ±ÇÇà"ñ°ÇµÇ<ÇÅB
ÉhÉLÉ\ÉãÉrÉVÉì
ÉAÉhÉäÉAÉVÉì
TM
çÏópÇÕÇªÇÍÇYÇ«ëÂÇ´ÇÇ»ÇÅAïópóñ@Ç
ÅiAÅj**
ÅiêíçÇÃÇ>Åj
égópÇÇÍÇÈ
åªéûì_ÇÇÕçúêëéÓÇÃçëPÇÃé°óÇÇµÇÉRÉìÉZÉìÉTÉXÇTMìæÇÁÇÍÇÇ¢ÇÈÇÇÃÇÕÇÇËÇ<Ç
ÅiVADÅAABCMÅAVMCP-VBAPÅj
ÇÒÇTMÅAà»âÇÕÇ¢ÇÇ¬Ç©ÇÃé°óÇÃÉKÉCÉhÉâÉCÉìÇÇÅB
ÉuÉXÉãÉtÉ@Éì*
Å¶
É}ÉuÉäÉì
TM
MÅACÇìØìôÇÃå¯â Çé¶ÇÅBí èÌÇÕëÂó
ÅiBÇ<ÇÇÕBUÅj**
Åiåoå°Ç<ÇÇÕêíçÅjâªäwóñ@Ç...égópÇÇÍÇÈ
çúêëéÓÇÕé°ñ¸ÇTMâ¬î\Ç»éæïaÇÇÕÇ»Ç¢ÇÃÇÅAçèâÇ...çsÇ§ÇÇ´çÇèdóvÇ»Ç±ÇÇÕÅAé°
ÅiBU/CYÇ»Ç«Åj
óÇTMïKóvÇ©Ç«Ç§Ç©ÇÃåàíËÇÇÅB
VP-16
Å¶
ÉxÉvÉVÉh
TM
çÏópÇÕÇªÇÍÇYÇ«ëÂÇ´ÇÇ»ÇÅAíPç<Ç<ÇÇÕ
MGUS
ÇÇÈÇ¢ÇÕñè«åÛê´çúêëéÓÅiÇÇÇ`ÇËå^çúêëéÓÅjÇÃèÍçáÇÕÅAé°óÇäJénÇµÇ» ÅiEÅj**
ÅiêíçÅj
ïópóñ@Ç...égópÇÇÍÇÈ
Ç¢Çñ»ñßÇ»äoeé@ÇçsÇ§ÇÇ´ÇÇµÇÂÇ§ÅBåªéûì_ÇÇÕÅAëÅäÇÃçúêëéÓÇ...Ç®Ç¢Çñâuî\ÇÉVÉXÉvÉâÉ`Éì
Å¶
ÉuÉäÉvÉâÉ`Éì
TM
íPç<ÇÇÕçè¨å¿ÇÃçÏópÇæÇTMÅAïópóñ@Ç
êèÌâªÇµÇÇËÅAêiçsÇó}êßÇµÇÇËÇÇ´ÇÈé°óñ@ÇÕëç>ÇµÇ<ÇÇÒÅBÇµÇ©Çµééå±íiäKÇ
ÅiCPÇ<ÇÇÕPÅj**
ÅiêíçÅj
égópÇÇÍÇÈ
ÇÕÇÇËÇ<ÇÇTMÅAçRÉCÉfÉBÉIÉ^ÉCÉvÉèÉNÉ`ÉìÇ»Ç«ÇÃé°óñ@ÇTMåüì¢ÇÇÍÇÇ¢Ç<ÇÅB
ÅiEDAPÅADT-PACEÅj
Çlê¨ïTMÇTMëùâ¡ÇµÇÇ¢ÇÈÅAÇÇÈÇ¢ÇÕâÇÁÇ©ÇÃó'èè«èÛÅiï\ÇPÇÃ
CRAB
ïTMófiÇéQèÅjÇTM
*ÉAÉãÉLÉãâªç<
**àÍî ìIÇ»óTMçÜÅ@Å¶ìñ{ÇÇÕñ¢èîF
16
17

âªäwóñ@
âªäwóñ@Ç...ÇÕäâì±ì¸âªäwóñ@ÅAëÂó âªäwóñ@ÅAéxéùóñ@ÇTMÇÇËÇ<ÇÅBàÍî Ç...ég
ópÇÇÍÇÈñÚç<ÇÕï\7Ç...ãLç/ÇµÇÇ¢Ç<ÇÅB
1962
îNÇÃìoèÍà»óàÅAÉÅÉãÉtÉ@ÉâÉìÇÕçúêëéÓé°
óÇ...Ç®Ç¢ÇçÇóLå¯Ç»ñÚç<ÇÇÅBì¡Ç...ÉvÉåÉhÉjÉ]ÉìÇÇÃïópÇÕÇYÇÇÒÇ«ÇÃäé"Ç...Ç®
Ç¢Çëtå¯ÇµÇ<ÇÅB
ibÉÅÉãÉtÉ@ÉâÉì/ÉvÉåÉhÉjÉ]ÉìÅiMPÅj
ÅAÉVÉNÉçÉzÉXÉtÉ@É~Éh/ÉvÉåÉhÉjÉ]ÉìÅiCPÅj
MPóñ@ÇÕçÇàÍî ìIÇ...çsÇÌÇÍÇÇ¢Ç<ÇÅBäé"ÇÃ
60ÅìÇTMëtå¯ÇµÅAçúêëéÓÉ^ÉìÉpÉNÇÃ
50Åìà»è,,ÇÃåèÇ...â¡Ç¶ÅAååéZílÇªÇÃÇYÇ©ÇÃåüçílÇÃâ¸ëPÅAçúí...Ç,îÊòJä¥Ç»Ç«ÇÃÇ
Ç<Ç¥Ç<Ç»è«èÛÇÃåyåÇTMìæÇÁÇÍÇ<ÇÅBÉVÉNÉçÉzÉXÉtÉ@É~ÉhÇÕÅAìØólÇ...çRçúêëéÓå¯â
ÇTMÇÇÈÇÇflÅAÉÅÉãÉtÉ@ÉâÉìÇÃë,,ë÷ÇÇµÇégópÇÇÍÇ<ÇÅBÉVÉNÉçÉzÉXÉtÉ@É~ÉhÇÕçú
êëÇÃë¢ååäçñEÇ÷ÇÃâeãøÇTMÇÊÇËåyìxÇÇÇËÅAë¢ååäçñEà/êAÇåüì¢ÇµÇÇ¢ÇÈäé"
Ç...Ç®Ç¢ÇÇÕé°óëIëéàÇÇ»ÇËÇ<ÇÅBÉÅÉãÉtÉ@ÉâÉìÇîärÇÇÈÇè¡âªäÌìê´Åià´êS
Ç»Ç«ÅjÇä<Çfië¶éûå^ÇÃïõçÏópÇTMÇÊÇËçÇïpìxÇ...å©ÇÁÇÍÇ<ÇÅB
ibëç<ïópóñ@
1960
îNë,,ÇÃíÜÇÇÎÇ©ÇÁàÍî Ç...égópÇÇÍÇÈñÚç<ÇÃëgÇ>çáÇÌÇÇ...ÇÊÇÈïópóñ@ÇTMééçs
ÇÇÍÇÇ¢Ç<ÇÅB
MPÇ<ÇÇÕ
CPÇîärÇµÅAÇÊÇËçÇÇ¢óLå¯ê´Çé¶Çâ¬î\ê´ÇÃÇÇÈïóp
óñ@Çï\8Ç...ãLç/ÇµÇ<ÇµÇÅB
M2ÉvÉçÉgÉRÅ[ÉãÇÕÉjÉÖÅ[ÉàÅ[ÉNÇÃÉÅÉÇÉäÉAÉãÉXÉçÅ[
ÉìÉPÉ^ÉäÉìÉOÇTMÇÒÉZÉìÉ^Å[ÇäJîÇÇÍÇ<ÇµÇÅBÇ¢ÇÇ¬Ç©ÇÃå§ãÜÇÇÕÅA
MPÇÇÃîär
Ç...Ç®Ç¢Ç
M2ÉvÉçÉgÉRÅ[Éãé°óåQÇTMÇÊÇËçÇÇ¢ëtå¯ó¶Çé°óê¨â Çé¶ÇµÇ<ÇµÇÅBçãfl
çsÇÌÇÍÇEastern Cooperative Oncology Group
ECO Åi
G
ÅjÇÃå§ãÜÇ...ÇÊÇÍÇOEÅA
M2Év
MP
èââÒé°óÇÃïWèÄ
ÉçÉgÉRÅ[ÉãÇé{çsÇÇÍÇäé"ÇÃëSêëÇÕ
MPÇÃÇªÇÍÇìØìôÇÇµÇÇTMÅA5îNêëÇ...Ç®
CP
MPÇÃë,,ë÷ÇÇµÇÇÊÇégópÇÇÍÇÈ
Ç¢ÇÇÕ
M2é°óåQÇTMóDÇÍÇÈÇ±ÇÇTMé¶ÇÇÍÇ<ÇµÇÅBÇÇæÇµìê´ÇÉRÉXÉgñ Ç...Ç®Ç¢ÇÇÕ
VBMCPÅiM2Åj
ÉAÉÅÉäÉJìåïîÇÇÊÇégópÇÇÍÇÈïópóñ@ÅB
MP
ÇÊÇËëtå¯ó¶ÇêëÇ...óDÇÍ
M2ÉvÉçÉgÉRÅ[ÉãÇTMóLóòÇÇÕåæÇ¶Ç<ÇÇÒÅB
VMCP/VBAP
óñ@Ç
ABCM
óñ@Ç...Ç®Ç¢Ç
ÇÈÇé¶ç¥ÇÇÍÇÈ
ÇìØólÇÃèÓïÒÇTMìæÇÁÇÍÇ<ÇµÇÅBÇ±ÇÍÇÁ2Ç¬ÇÃé°óñ@ÇÕ
MPÇÇÃîärÇ...Ç®Ç¢ÇóDà ê´
VMCP/VBAPSWOGÇ...ÇÊÇ¡ÇäJîÇÇÍÇïópóñ@ÅAÉAÉÅÉäÉJêºïîÇÇÊÇégópÇÇÍÇÈÅB
Çé¶ÇµÇ<ÇµÇÇTMÅAìê´ÇÉRÉXÉgÇÃñ
MP
ÇÇÕ
Çí¥Ç¶ÇÈÇ±ÇÇÕÇÇ´Ç<ÇÇÒÅBíîNÇ±ÇÍ
ìê´ÇTMãÇ¢äÑÇ...ïtâ¡ìIÇ»óLópê´ÇTMèÇ»Ç¢ÇÃÇÕM2ÇìØól
ÇÁÇÃëç<ïópóñ@Çé{çsÇµíÒè·ÇµÇÇ¢ÇÈå§ãÜé"ÇÇøÇÕÅAé°óê¨â
MPÇÕèÇ»ÇÇÇ
ABCM
ÉàÅ[ÉçÉbÉpÅAì¡Ç...ÉCÉMÉäÉXÇÇÊÇégópÇÇÍÇÈïópóñ@ÅB
MP
ÇÇÃîärÇ
ÇìØìôÇÇÇËÅAÇÌÇÇ©Ç»ÇTMÇÁÇóDÇÍÇÇ¢ÇÈâ¬î\ê´ÇTMÇÇÈÇ±ÇÇ©ÇÁÅAÇ±ÇÍÇÁÇÃïóp
ÇÕóDà ê´ÇÕÇYÇÇÒÇ«îFÇflÇÁÇÍÇ»Ç¢
óñ@ÇÃégópÇêÑèßÇµë±ÇØÇÇ¢Ç<ÇÅBåªç>ÇÇÕÅAëÊàÍëIëÇÇµÇ
MPÇ<ÇÇÕ
CPÇé{
VAD
MPÇÃë,,ë÷ÇÇµÇçÇÇÊÇégópÇÇÍÇÈÅB
çsÇµÅAè\ïTMÇ»å¯â ÇTMìæÇÁÇÍÇ»Ç©Ç¡ÇèÍçáÇ...îiÇ¶ÅAÇ±ÇÍÇÁÇÃëç<ïópóñ@ÇÃëIëéà
ì¡Ç...à»âÇÃèÍçá
ÇécÇµÇÇ®ÇÇÇ¢Ç§åXå¸ÇTMÇÇËÇ<ÇÅB
ÅEçúêëéÓÇÃäàìÆê´ÇTMçÇÇ¢
ÅEêtïsëSÇîÇ§
ÅEà/êAÇîÇ§ëÂó óñ@ÇTMó\íËÇÇÍÇÇ¢ÇÈ
ååíÜÇ<ÇÇÕîAíÜÇÃçúêëéÓÉ^ÉìÉpÉNÇÃåÄìIÇ»åèÇTMÅAïKÇÇµÇÇÊÇËíÇ¢äâÇ,êë
DÇ<ÇÇÕ
M D
Ç< DíPìÇÇÈÇ¢ÇÕMÇ<ÇÇÕCÇÇÃïópÇÕ
VAD
ÇÃë,,ë÷ÇÇµÇégópÇÇÍÇÈÅB4
ÇÇÇÇÁÇÇ»Ç¢ÇÇ¢Ç§éñé¿ÇÕÅAçúêëéÓÇÃé°óÇç¨óêÇÇÇÈë§ñ ÇÇÅBé°óê¨â Çåà
ÇÇÕCD
ìä`ÇÃéùë±ì_ìHÇTMïsóv
18
19

é°óå¯â ÇÃÉÇÉjÉ^ÉäÉìÉO
é°óå¯â ÇîªífÇÇÈè,,ÇçÇèdóvÇ»Ç±ÇÇÕÅAé°óäJénéûÇÃè«èÛÇTMâ¸ëPÇÇÍÇÇ©Ç«Ç§
Ç©ÇämîFÇÇÈÇ±ÇÇÇÅBÇªÇÍÇ...ÇÕååâtåüçÇ,êâªäwåüçÇÃÉfÅ[É^ÇÃâ¸ëPÇ,ÅAååê¥Ç
ÇÈÇ¢ÇÕîAíÜÇÃçúêëéÓÉ^ÉìÉpÉNÇÃåèÇTMä<Ç<ÇÍÇ<ÇÅBçúêëéÓÇÃïaê®ÇëTMÇÈèdóvÇ»É}Å[
ÉJÅ[ÅiéwïWÅjÇ...ÇÕÅAååê¥É¿
2É~ÉNÉçÉOÉçÉuÉäÉìÅAÇbîâûê´É^ÉìÉpÉNÅAññèååÇ<ÇÇÕçú
êëÇÃÉâÉxÉäÉìÉOÉCÉìÉfÉbÉNÉXÇTMãìÇÇÁÇÍÇ<ÇÅBÉxÉìÉXÉWÉáÅ[ÉìÉYÅEÉ^ÉìÉpÉNÇÃóLñ
ÇämîFÇÇÈÇÇflÅAíËäìIÇ...
24éûä`ÇÃí~îAåüçÇçsÇ§Ç±ÇÇëÂêÿÇÇÅBíËäìIÇ...çúÇÃX
ê¸åüçÇçsÇ¢ÅAêVÇÇ»ïaïoeÇå©ì¶ÇÇ±ÇÇÃÇ»Ç¢ÇÊÇ§Ç...óØà"ÇµÇ<ÇÅBÇÇÁÇ...
MRI
Ç,CT
Ç...ÇÊÇÈåüçÇçsÇ¢ÅAçúÇÃèÛë`ÇÇÊÇËè/çÇ...ï]âøÇÇÈÇ±ÇÇïKóvÇ©ÇÇµÇÍÇ<ÇÇÒÅB
DEXAÉXÉLÉÉÉìÇÕçúñßìxÇÃÉxÅ[ÉXÉâÉCÉìÇêîó âªÇµÅAåoâfläoeé@Ç...ópÇ¢ÇÁÇÍÇ<ÇÅB
ï\ÇXÅ@é°óå¯â ÇÃÉÇÉjÉ^ÉäÉìÉOÇ...ïKóvÇ»åüç
ååâtåüç
ÅEååéZílÅiíËäìIÇ...çsÇ§Åj
ÅEêâªäwåüç
ÅEäÃã@î\
ÅEÇlÉ^ÉìÉpÉNÅiååê¥É^ÉìÉpÉNìdãCâjìÆÅ{ñâuÉOÉçÉuÉäÉìÅj
ÅEååê¥É¿
2É~ÉNÉçÉOÉçÉuÉäÉì
ÅECRPÅiCîâûê´É^ÉìÉpÉNÅj
ÅEññèååÉâÉxÉäÉìÉOÉCÉìÉfÉbÉNÉX
ÅEååê¥ÉGÉäÉXÉçÉ|ÉGÉ`Éì
îA
ÅEîAåüçÅiíËäìIÇ...çsÇ§Åj
ÅE24éûä`í~îAåüçÅiëçÉ^ÉìÉpÉNÅAÉ^ÉìÉpÉNìdãCâjìÆÅAñâuìdãCâjìÆÅj
ÅEååê¥CrílÇÃè,,èéûÇÕ24éûä`CcrÅiÉNÉåÉAÉ`ÉjÉìÉNÉäÉAÉâÉìÉXÅj
çú
ÅEçúÉGÉbÉNÉXê¸ëú
ÅEMRI/CTÉXÉLÉÉÉìÅióLè«èÛÇÃèÍçáÅj
ÅEFDG/PETÇ...ÇÊÇÈëSêgÇÃåüçÅiïaèÛÇTMïsñæÇ»èÍçáÅj
ÅEçúñßìxÅiDEXAÉXÉLÉÉÉìÅj
ÅiÉxÅ[ÉXÉâÉCÉìÇ®ÇÊÇ--ÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égé°óå¯â ï]âøÇÇµÇÅj
çúêë
ÅEçúêëêéhÇ®ÇÊÇ--çúêëêåü
ÅiêfífÇ®ÇÊÇ--íËäìIÇ»ÉÇÉjÉ^ÉäÉìÉOÇÃÇÇflÅj
ÅEó\å,,ÇÃï]âøÅi13î`êiêFëÃÇÃàYèÌÅAñâuåüçÅALIÅìÅj
ÇªÇÃëºÇÃåüç ÅEÉAÉ~ÉçÉCÉhÅ[ÉVÉX
Åiì¡ï Ç»èÍçáÅj ÅEÉjÉÖÅ[ÉçÉpÉVÅ[
ÅEêtÇ<ÇÇÕä¥êiÇÃçáïè«
20
21

ÅiQuality of Life: êäàÇÃéøÅjÇÕèdóvÇ»åüì¢â¤ëËÇÇÅBà/êAé°óÇéñëOÇ...åvâÊÇµÇçsÇÌ
Ç»Ç¢èÍçáÅAà¤éùóñ@Çä<Çfié°óÇí«â¡ÇµÇéÛÇØÇÈÇ±ÇÇ...Ç»ÇËÇ<ÇÇTMÅAÇ±ÇÍÇÁÇÃé°ó
ÇÕìê´ÇÇÈÇ¢ÇÕïõçÏópÇîÇ¢Ç<ÇÅBàÍï°Çà/êAé°óÇ...îÇ§èdëÂÇ»âeãøÇÕÇÇÇ<Çî
ÇØÇÁÇÍÇ<ÇÅBà/êAÇâÑäÇµÇï°ÇTMÇ¢Ç¢Ç©Ç«Ç§Ç©ÇÕäé"ÇªÇÍÇºÇÍÇÃëIëÇ...îCÇÇÈÇÇ´
ÇÇµÇÂÇ§ÅB
ë¢ååäçñEÇÃçÃéÊÇï¤ë
ë¢ååäçñEà/êAÇÃéûäÇTMåàíËÇµÇÇ¢Ç»Ç¢èÍçáÅAì¡Ç...íºÇøÇ...é{çsÇµÇ»Ç¢èÍçáÇÕÅAëÇ
ÇÃé{ê>ÇÇÕë¢ååäçñEÇÃçÃéÊÇ...è¡ã...ìIÇÇÅBÇªÇ±Ç...ÇÕé°óåvâÊè,,ÇÃóDêÊèáà Ç,çÃ
éÊÅEï¤ä«ÇÃîÔópÇÇÕÇÇflÅAëÇÇÃñ,ëËÇTMâeãøÇµÇÇ¢Ç<ÇÅBÇµÇ©ÇµÇ»ÇTMÇÁÅAÇÇÇ¶ëÂ
ó óñ@ÇíºÇøÇ...é{çsÇÇÈÇ±ÇÇ...êoeã...ìIÇÇ»Ç¢äé"ÇÇÅAëÇÇÕë¢ååäçñEÇçÃéÊÇ
ÇÈÇ±ÇÇäÛñ]ÇµÇ<ÇÅB
êÑèßÇÇÍÇÈÇ±Ç
a. è´óàégópÇÇÈÇÇflÇ...çÃéÊÅEï¤ëÇÇÈÇ±ÇÇÕÅAå¬ï ÇÃéñèÓÇåüì¢ÇµÇÇ§Ç¶ÇêÑèßÇ
ÇÍÇ<ÇÅB
b. ë¢ååäçñEÇÃï¤ëÇ...ÇÕà,,äwìIÇ®ÇÊÇ--â»äwìIÇ»ò_ãíÇTMëç>ÇµÇ<ÇÅB
c. à/êAÇâÑäÇÇÈÇ±ÇÇÕâ¬î\ÇÇÅBìÒìxñ/ÇÃà/êAÇÕÅAì¡Ç...èââÒÇÃäâää`ÇTMÇQîNà»
è,,ÇÇ¡ÇèÍçáÅAé¿çsâ¬î\Ç»ëIëéàÇÇÅB
ÅiâãLÇÃìÒâÒà/êAÇ...ä÷ÇÇÈèÕÇéQèÇµÇÇ
ÇæÇÇ¢Åj
ìÒâÒÅiÉ^ÉìÉfÉÄÅjà/êAÇÃñäÑ
ibåªéûì_ÇÇÕìÒâÒà/êAÇÃñäÑÇÕñæämÇÇÕÇÇËÇ<ÇÇÒÅB
ibèâäÇ...çsÇÌÇÍÇìÒâÒà/êAÅiÉAÅ[ÉJÉìÉ\Å[ëÂäwÇ...ÇÊÇÈTotal
II
Therapy
ÅjÇÇÕó«çD
IÇ
Ç»åãâ ÇTMìæÇÁÇÍÇÇ¢Ç<ÇÅBëSêëÇÃíÜâõílÇÕ
68ÉJåéÇÅAÇ¢ÇÇ¬Ç©ÇÃÉOÉãÅ[ÉvÇÇÕ
ÇªÇÍà»è,,ÇÃíäêëÇTMìæÇÁÇÍÇÇ¢Ç<ÇÅB
ibÇµÇ©ÇµÇ»ÇTMÇÁÅAÉtÉâÉìÉXÇÃñçÏàâªééå±Ç»Ç«ÅAçãflé¿é{ÇÇÍÇîärééå±ÇÇÕÅAët
å¯ó¶Çêëó¶Ç...Ç®Ç¢ÇÇÌÇÇ©Ç»óDà ê´ÇµÇ©é¶ÇÇ<ÇÇÒÇÇµÇÅBÇÊÇËíäÇÃí«ê'í
çÇ...ÇÊÇËìÒâÒà/êAÇÃóDà ê´ÇTMí«â¡ÇÇÍÇÈÇ©ÇÇµÇÍÇ<ÇÇÒÅB
êÑèßÇÇÍÇÈÇ±Ç
a. åªéûì_ÇÇÕåvâÊìIÇ»ìÒâÒà/êAÇÕàÀëRÇÇµÇó'èééå±ÇÃíiäKÇÇÇËÅAà/êAåoå±ÇÃñL
ïxÇ»é{ê>Ç...Ç®Ç¢Çé¿é{ÇÇÍÇÈÇÇ´ÇÇÅB
b. èââÒÇÃà/êAÇ...ÇÊÇîâûÇµÇäé"Ç,ÇQîNà»è,,ÇÃäâää`ÇTMìæÇÁÇÍÇäé"Ç...ä÷ÇµÇÇÕÅA
ìÒâÒñ/ÇÃà/êAÇÕóLópÇ©Ç¬é¿çsâ¬î\ÇÇÅB
ÅiSirohi 2001Åj
22
23

ï\10
ëÂó âªäwóñ@Çà/êA
éÌófi
óòì_
åáì_
ÅE
50ÅìÇ...Ç®Ç¢Çó«çDÇ»äâÇTMìæÇÁ
ÅEçîÉpÉ^Å[ÉìÇÕïWèÄâªäwóñ@Ç
ÇÍÇÈ
ófiéóÇµÇÇ¢ÇÈ
ÅEèÇ»ÇÇÇëSêëÇ...Ç®Ç¢ÇÇÕïW
ÅEìê´ÇTMãÇÉRÉXÉgÇTMÇ©Ç©ÇÈ
èÄé°óÇìØìôÇÇÇËÅASÉ¿
2M
çÇ ÅEâåbÇéÛÇØÇÈäé"ëwÇTMñæämÇ...Ç»
ílÇÃäé"Ç...ëOEÇµÇÇÕÇÊÇËìKêÿÇ»
Ç¡ÇÇ¢Ç»Ç¢
é©âà/êA
é°óñ@ÇévÇÌÇÍÇÈ
ÅEà¤éùóñ@ÇïKóvÇÇÇÈÅiÉCÉìÉ^
ÅiàÍâÒÅj ÅEäÆëSäâÅAíäÇÃäâÇìæÇÈé°
Å[ÉtÉFÉçÉìÅAÉvÉåÉhÉjÉ]ÉìÅAÉè
óêÌóTMÇÃäÓî'ÇÇÇÈ
ÉNÉ`ÉìÇ»Ç«Åj
ÅEé°ñ¸ÇìæÇÈÇÇflÇ...ÇÕêVÇÇ»ëOèà
íuÇÃÉåÉWÉÅÉìÇÃäJîÇTMäë"ÇÇÍ
ÇÈ
ÅEàÍâÒà/êAÇìØól
ÅEàÍâÒà/êAÇÇÃîärÇµÇÇÇ´ÇÃóD
é©âà/êA ÅE
2002
îNÇÃÉtÉâÉìÉXÇÃÉfÅ[É^ÇÇÕ
à ê´ÇÕàÀëRÇÇµÇñæämÇÇ»Ç¢
ÅiìÒâÒÅj
àÍïîÇÃäé"Ç...Ç®Ç¢Çêëó¶ÇÃóD
ÅEàÍâÒà/êAÇÊÇËìê´ÇTMãÇÅAÇµÇ©
à ê´Çé¶ÇµÇ
ÇîÔópÇTMÇ©Ç©ÇÈ
ÅEà/êAïÇ...çúêëéÓçñEÇTMç¨ì¸ÇµÇ»
ÅE
HLA
äÆëSàÍívÇÃåZíÌéoñÖä`ÇÇ
Ç¢
Ç¡ÇÇëÅäÇÃçáïè«ÇÃîåªÇ,é°
ÅEà/êAïëOEéÓ·áÅiçúêëéÓÅjå¯â Ç...
óä÷òAéÄÇÃÉäÉXÉNÇTMÇÇÈÅi
25-
ÇÊÇËäâÇTMâÑíÇÇÈâ¬î\ê´ÇTMÇ
30ÅìÅj
è]óàå^ÇÃ
ÇÈ
ÅEñ¢ímÇÃçáïè«ÇTMîåªÇÇÈÉäÉXÉN
ìØéÌà/êA
ÇTMÇÇÈ
ÅE55çOEñ¢ñûÇ...å¿íËÇÇÍÇÈ
ÅEé©âà/êAÇ...îÇÇÇÊÇËìê´ÇTMã
ÇÅAÇÊÇËîÔópÇTMÇ©Ç©ÇÈ
ÅEè]óàå^ÇÃìØéÌà/êAÇÊÇËìê´ÇTMåy
ÅEëOèàíuÇÇµÇçúêëéÓçñEÇÇÇ
ìxÇÇÇÈ
Çâªäwóñ@ÇçsÇÌÇ»Ç¢
ÅEëOèàíuÇÃîEóeê´ÇTMçÇÇ¢ÅEà/êAïëOEèhéÂïaÇTMîåªÇÇÈ
É~Éjà/êA ÅEà/êAïëOEéÓ·áÅiçúêëéÓÅjå¯â Ç
ÅEóLópê´ÇÃëSñeÇÕÇ¢Ç<Çæïsñæäm
ÇÇÇÁÇ
ÅEëÅäÇÃé°óä÷òAéÄÇÃÉäÉXÉNÇTMí·
Ç¢Åi1-3ÅìÅj
ÅEà/êAïÇ...çúêëéÓçñEÇTMç¨ì¸ÇµÇ»
ÅEà/êAïëOEéÓ·áÅiçúêëéÓÅjå¯â ÇÕ
Ç¢
Ç»Ç¢
ëoêéôà/êA ÅEìØéÌà/êAÇÊÇËÉäÉXÉNÇTMí·Ç¢
ÅE
55çOEà»âÇàÍóëê´ëoêéôÉhÉiÅ[
ÇTMëç>ÇÇÈäé"Ç...å¿íËÇÇÍÇÈ
24
25

âÇêëÇâÑíÇÇÇÈé°óñ@Çå©Ç¬ÇØÇÈÇ±ÇÇÕç¢ìÔÇÇµÇÅBÇµÇ©ÇµÇ»ÇTMÇÁ
1980
îN
ë,,Ç©ÇÁÉvÉåÉhÉjÉ]ÉìÇTMà¤éùóñ@ÇÇµÇóLå¯ÇÅAÉAÉãÉtÉ@ÉCÉìÉ^Å[ÉtÉFÉçÉìÇÊÇËóD
å`éøçñEÇTM
ÇÍÇÈâ¬î\ê´ÇTMÇÇÈÇçlÇ¶ÇÁÇÍÇÇ¢Ç<ÇµÇÅBçãflÇÃå§ãÜÇ...ÇÊÇËÅAÉvÉåÉhÉjÉ]ÉìÇÃóL
îjçúçñEÇ
éhåÉÇÇÈ
å¯ê´ÇÕÇÇÁÇÇflÇîFÇflÇÁÇÍÇ<ÇµÇÅBèT3âÒÇÃÉvÉåÉhÉjÉ]Éììäó^Åió·ÅFèââÒìäó^ó
50
çúÇTMóZÇØÇ
çúêëéÓçñEëùêBà^éqÇ
iÊÅjÇÕìê´ÇÃñ ÇÇîEóeâ¬î\ÇÇÇËÅAäâÇêëÇâÑíÇµÇ<ÇÅBÉvÉåÉhÉjÉ]ÉìÇTM
ïèoÇÇÈ
çúêë
ñÚç<ëoeê´ÇåªÇÇÇ...êîîNä`äâÇà¤éùÇµìæÇÈÇ±ÇÇÕÅAç¤óßÇ¡Çóòì_ÇåæÇ¶ÇÈÇÇµ
ÇÂÇ§ÅBÇÇæÇµÅAíäìäó^Ç...ÇÊÇÈïõçÏópîåªÇ...ÇÕíçà"ÇµÇ»ÇØÇÍÇOEÇ»ÇÁÇÅAí èÌÅAìä
ó^ó ÇÃåó ÇTMïKóvÇÇ»ÇËÇ<ÇÅB
ãzé°ÇÇÍÇÇ¢ÇÈ
çúÇÃï\ñ
éxéùóñ@
ibÉGÉäÉXÉçÉ|ÉGÉ`Éì
ÉGÉäÉXÉçÉ|ÉGÉ`ÉìÅiÉGÉ|ÉWÉì
T M
ÅAÉGÉXÉ|Å[
T M
Ç»Ç«ÅjÇÕëÃìÇêê¨ÇÇÍÇÈÉzÉãÉÇÉìÇÃ
àÍÇ¬ÇÇÇTMÅAåªç>ÇÇÕà,ì`éqçHäwãZèpÇ...ÇÊÇ¡Ççáê¨ÇÇ´ÇÈÇÊÇ§Ç...Ç»ÇËÇ<ÇµÇÅBÉG
ÉäÉXÉçÉ|ÉGÉ`ÉìÇÕìÔé°ê´ïnååÇëOEè¤Ç...ÉwÉÇÉOÉçÉrÉìílÇÃâ¸ëPÇñ/ìIÇÇµÇégópÇ
ÇÍÇÇ¢Ç<ÇÅBÉGÉäÉXÉçÉ|ÉGÉ`ÉìÇÃìäó^Åió·ÅFÇSñúíPà Å^èT
îÁâìäó^ÅjÇÕÅAÉwÉÇÉO
ÉçÉrÉìílÇÃè,,èÇàÍî èÛë`Åi
PSÅjÇÃâ¸ëPÇ...åÄìIÇ»å¯â ÇåªÇµìæÇ<ÇÅBìÔé°ê´ïnåå
ÇÃäé"Ç...Ç®Ç¢ÇÇÕÇªÇÃégópÇÇÇåüì¢ÇÇÈÇÇ´ÇÇÅBÉGÉäÉXÉçÉ|ÉGÉ`ÉìÇÃåpë±ég
ópÇÕÅAñæämÇ»å¯â ÇTMìæÇÁÇÍÇäé"Ç...å¿ÇËçsÇ¢Ç<ÇÅBçëÂå¿ÇÃå¯â ÇìæÇÈÇÇflÇ...ÇÕ
ìSïTMÇÃï,ããÇTMïKóvÇ©ÇÇµÇÍÇ<ÇÇÒÅB
Å¶ñÛíçÅFÉGÉäÉXÉçÉ|ÉGÉ`ÉìÇÃìñ{ÇÇÃï¤åØìKópÇÕìßêÕì±ì¸ëOÅEêtê´ïnååÇÃÇ>
ibÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<
ÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<ÇÕçúêëéÓäé"ÇÃëèùÇµÇçúÇÃï\ñ ÇèCïúÇÇÈâªäwï®éø
ÇÇÅBçúÇÃï\ñ ÇèCïúÇÇÈçÏópÇ...ÇÊÇËÅAçúîjâÛÇÃêiçsÇTMó}êßÇÇ´ÇÈÇæÇØÇÇ»ÇÅA
èùÇÒÇæçúÇÃâÒïúÇ,çúÇÃñßìxÇãìxÇâ¸ëPÇÇÈå¯â Çäë"ÇÇ´Ç<ÇÅBãflîNé¿é{ÇÇÍ
ÇñçÏàâªééå±Ç...ÇÊÇÍÇOEÅAÉpÉ~ÉhÉçÉlÅ[ÉgÅiÉAÉåÉfÉBÉA
T M
ÅjÇÃégópÇÕÅAâªäwóñ@
Ç...îâûÇµÇÇ¢ÇÈäé"Ç...Ç®Ç¢ÇÇÇËÇÌÇØóDà ê´ÇTMîFÇflÇÁÇÍÇ<ÇµÇÅBåªç>ÇÇÕÉpÉ~Éh
ÉçÉlÅ[ÉgÇÃìäó^ÇÕçúè«èÛÇîÇ§çúêëéÓÇ...ëOEÇÇÈï,èïóñ@ÇÇµÇêÑèßÇÇÍÇÇ¢Ç<ÇÅB
ÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<Ç...ÇÕÇYÇ©Ç...ÇÅAÉàÅ[ÉçÉbÉpÇçúêëéÓÇÃé°óÇ...égópÇÇÍ
ÇÇ¢ÇÈåoå°ç<ÇÃÉNÉçÉhÉçÉlÅ[ÉgÇ,ÅAçãflÉAÉÅÉäÉJÇÉàÅ[ÉçÉbÉpÇçÇÉJÉãÉVÉEÉÄåå
è«Ç®ÇÊÇ--çúïaïoeÇÃâ¸ëPÇëOEè¤ÇÇµÇèîFÇÇÍÇÉ]ÉåÉhÉçÉlÅ[ÉgÅi
Zometa
T M
ÅjÇ»Ç«
ÇTMÇÇËÇ<ÇÅBêVãKÇÃÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<ÇÃó'èééå±ÇêiÇÒÇÇ¢Ç<ÇÅB
Å¶ñÛíçÅFÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<ÇÃìñ{ÇÇÃï¤åØìKópÇÕçÇÉJÉãÉVÉEÉÄååè«ÇÃÇ>
26
27

ÇÃäâì±ì¸é°óÇ©ÇÁÇPîNà»è,,åoâflÇµÇÇ¢ÇÈèÍçáÇÕì¡Ç...å¯â Çäë"ÇÇÈÇ±ÇÇTMÇÇ´Ç<
ÇÅBó·Ç¶ÇOEÅA
MPóñ@å,,ÇQîNä`ÇÃäâää`ÇTMåoâflÇµÇÇ¢ÇÍÇOEÅAçÇ--
MPóñ@ÇTMçsÇ¶Ç<
ÇÅBäâää`ÇTMÇUÉJåéñ¢ñûÇÃèÍçáÇÕÅAÇYÇ©ÇÃé°óñ@ÇTMïKóvÇÇ»ÇËÇ<ÇÅBÇ±ÇÍÇÕèââÒ
ÇìØÇäâì±ì¸é°óÇìÒìxéOìxÇåJÇËï`ÇµÇå,,ÇÃçîÇ...Ç®Ç¢ÇÇåæÇ¶ÇÈÇ±ÇÇÇÅB
Ç±ÇÃÇÊÇ§Ç»ÇÇ´Ç...ÇÕ
VAD
óñ@ÇTMèdóvÇ»ëIëéàÇÇ»ÇËÇ<ÇÅB
VAD
óñ@Ç...ë¨Ç,Ç©Ç...îâû
Çé¶ÇÇ»Ç¢èÍçáÇÕÅA
VAD
óñ@Ç...
PSC833
Åiëç<ëoeê´ÇçéïûÇÇÈÇÇflÅjÇ,
Doxil
Åiíéû
ä`çÏópå^ÉAÉhÉäÉAÉ}ÉCÉVÉìÅjÇ»Ç«ÇÃêVãKñÚç<ÇÃïópÇåüì¢ÇµÇ<ÇÅB
Åiê}ÇUÅj
P-ìúÉ^ÉìÉpÉNÇTM
çúêëéÓçñEÇÃ
ï\ñ ÇÇ®Ç®Ç§
P-ìúÉ^ÉìÉpÉNÇTM
ÉAÉhÉäÉAÉ}ÉCÉVÉìÇÇÇ>èoÇµÅA
çúêëéÓçñEÇéÁÇÈ
ÉAÉhÉäÉAÉ}ÉCÉVÉìÇTM
çúêëéÓçñEÇ...ìÀì¸
ê}ÇUÅFëç<ëoeê´ÇÃçúêëéÓçñE
çîÅEé°óíÔçRê´çúêëéÓÇéÊÇËëgÇfiÇÇflÇ...ÅAÇÇ<Ç¥Ç<Ç»ñÚç<Ç,ïópâªäwóñ@ÇÃÉv
ÉçÉgÉRÅ[ÉãÇTMóòópâ¬î\Ç»ÇÃÇÅAêSÇ...óØÇflÇÇ®ÇÇ±ÇÇTMèdóvÇÇÅBé¿ç¤ÇÃâ¤ëËÇ...ÇÊÇËÅA
ÇÇ¢é~ÇflÇÈï°ñ@ÇÕÇ¢ÇÎÇ¢ÇÎóLÇËìæÇ<ÇÅBó·ÇãìÇÇÈÇÅAçîÇTMàÍÅAìÒÉJèäÇÃçúïaïoe
ÇîÇ¡ÇÇ¢ÇÈèÍçáÇÕÅAçúïaïoeÇÃãNÇ´ÇÇ¢ÇÈã«èäÇ÷ÇÃïéÀê¸é°óÇ...ÇÊÇËè\ïTMÇ...ä«óùÇ
Ç´ÇÈâ¬î\ê´ÇTMÇÇËÇ<ÇÅBëSêgÇ...çîÇTMãNÇ±Ç¡ÇÇÇ´ÇÕÅAÉfÉLÉTÉÅÉ^É]ÉìÇÃíPç<Çïa
èÛëSëÃÇÉRÉìÉgÉçÅ[ÉãÇÇ´ÇÈâ¬î\ê´ÇTMÇÇËÇ<ÇÅBÉfÉLÉTÉÅÉ^É]ÉìÇÕåoå°ìäó^ÇTMâ¬î\
ÇÅAíEñ--Ç,ññèååéZílÇÃí·âÇ»Ç«åíòÇ»ïõçÏópÇTMîåªÇµÇ»Ç¢ÇÃÇñ£óÕìIÇÇÅB
ëÂó âªäwóñ@Åié©âà/êAÅjå,,ÇÃçîÇèdóvÇ»â¤ëËÇÇÇTMÅAÇYÇÇÒÇ«ÇÃèÍçáÅAïWèÄ
ìIÇ»âªäwóñ@å,,ÇÃçîÉpÉ^Å[ÉìÇ...ófiéóÇµÇÇ¢Ç<ÇÅBçúêëà/êAå,,ÇÃçîÇ...Ç®Ç¢ÇÇìÒ
ìxÅAéûÇ...ÇÕéOìxñ/ÇÃäâÇìæÇÈÇ±ÇÇTMâ¬î\ÇÇÅBçÇ--ëÂó óñ@Åié©âà/êAÅjÇçsÇ§
ÇÃÇTMçìKÇ»ÇÃÇ©ÅAÇªÇÍÇÇí èÌó ÇÃâªäwóñ@ÇÇÊÇ¢ÇÃÇ©ÇÕÅAåªéûì_ÇÇÕñæämÇ...Ç»Ç¡
ÇÇ¢Ç<ÇÇÒÅBÉçÉìÉhÉìÇÃÉçÉCÉÑÉãÉ}Å[ÉYÉfÉìïaâ@ÇÇÕ
1980
îNë,,èâìTMÇ©ÇÁîºÇOEÇ...Ç©ÇØ
ÇçÇópó ÉÅÉãÉtÉ@ÉâÉìÇ...ÇÊÇÈëÂó óñ@Åié©âà/êAÅjÇÇQÅ`ÇRâÒÇÇÈé°óÇçsÇ¢ÅAó«
çDÇ»åãâ ÇìæÇÇ¢Ç<ÇÅBèdóvÇ»Ç±ÇÇÇµÇÅAÇ±ÇÃìØÇäé"åQÇÕÉAÉãÉtÉ@ÉCÉìÉ^Å[Ét
ÉFÉçÉìÇÃà¤éùóñ@ÇTMëÂó óñ@å,,ÇÃäâäÇÃéøÇíÇÇ...äÒó^ÇÇÈÇ±ÇÇé¶ÇµÇÇ±ÇÇ
ì¡ïMÇµÇ<ÇÅB
28
29

éQèÇµÇÇÇæÇÇ¢ÅB
çúè«èÛÇÃêVÇÇ»é°ó
çúÇÃëèùÇÕçúêëéÓäé"ÇÃêgëÃìIÇ»è·äQÇÃéÂóvå¥à^Ç»ÇÃÇÅAêVÇÇ»ñÚç<ÇÃìoèÍÇTMä
ë"ÇÇÍÇ<ÇÅBè]óàÇÃÉrÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<ÇóLå¯ÇÇÇTMÅAÇÊÇËãóÕÇ»êVÇµÇ¢Ér
ÉXÉtÉHÉXÉtÉHÉlÅ[Égêªç<ÇTMÇ¢ÇÇ¬Ç©ìoèÍÇµÇ<ÇµÇÅBÇªÇÍÇÁÇÃñÚç<ÇÃå¯â ÇÇµÇÇÕÅA
çúÇâÒïúÇÇÈÇæÇØÇÇ»ÇÅAçúêëíÜÇÃçúêëéÓçñEÇÃëùêBÇÃó}êßÅiåíòÇ»çRÇTMÇÒçÏópÇ»
Ç«ÅjÇTMäë"ÇÇÍÇÇ¢Ç<ÇÅBÇÇÁÇ...íëÃå`ê¨èpÇÇ¢Ç§çúêëéÓäé"Ç...óLópÇ»êVÇµÇ¢é°ó
ñ@ÇTMäJîÇÇÍÇÇ¢Ç<ÇÅBÇ±ÇÍÇÕíëÃÇÃàîóçúê<Ç...ëOEÇµÉvÉâÉXÉ`ÉbÉNÉZÉÅÉìÉgÇíçì¸
ÇÇÈÇ±ÇÇ...ÇÊÇ¡ÇÅAíëÃãìxÇï,ãÇµêgíÇÃí·âÇ,ê"íÇÃòpã»ÇÃâ¸ëPÇÇÇÇÁÇÇ
Ç¢Ç§é°óñ@ÇÇÅBÇ±ÇÍÇ<ÇÇÃÇÇ±ÇÎäë"ÇÇ´ÇÈåãâ ÇTMìæÇÁÇÍÇÇ¢Ç<ÇÅBÇªÇÃÇYÇ©ÅA
ÉXÉ^É`ÉìånñÚç<ÅiçÇéâååè«é°óñÚÅjÇTMçúè«èÛÇÃâÒïúÇ...óLå¯Ç©Çåüì¢ÇÇÈó'èééå±ÇTM
é¿é{ÇÇÍÇÇ¢Ç<ÇÅB
êVãKâªäwóñ@ç<
Ç¢ÇÇ¬Ç©ÇÃêVÇÇ»âªäwóñ@ç<ÇTMçúêëéÓÇÃé°óÇ...ì±ì¸ÇÇÍÇÇ¢Ç<ÇÅBçãflé¿é{ÇÇÍ
ÇÉXÉyÉCÉìÇÇÃå§ãÜÇ...ÇÊÇËÉrÉmÉåÉãÉrÉìÅiÉiÉxÉãÉrÉì
T M
ÅjÇÉfÉLÉTÉÅÉ^É]ÉìÇÃïóp
ÇÕÅAí èÌÇÃâªäwóñ@Ç,ëÂó óñ@Åié©âà/êAÅjå,,ÇÃçîÇ...Ç®ÇØÇÈäâì±ì¸ñ@ÇñÕçiÇµ
ÇÇ¢ÇÈäé"Ç...ÇÇ¡ÇÅAÇ©Ç»ÇËäÛñ]ÇÃéùÇÇÈé°óñ@ÇÇÇÈÇ±ÇÇTMé¶ÇÇÍÇ<ÇµÇÅBÉCÉ`
ÉCâ»ÇÃêAï®óRóàÇÃÉ^ÉLÉTÉìånñÚç<ÇÇÇÈÉ^ÉLÉ\Å[Éã
T M
ÇÉ^ÉLÉ\ÉeÅ[Éã
T M
ÇÕÅAÉgÉ|ÉeÉJ
ÉìÅiñÚï®ëoeê´çñEÇÃë,,é"ÇëjäQÇÇÈÅjÇìØólÇ...ÅAçîÅEé°óíÔçRê´çúêëéÓÇ...âÇÁÇ©
ëÊáTëäééå±
îEóeê´Ç®ÇÊÇ--ìê´ÇÃï]âøÇçsÇ§
ÇÃçÏópÇTMÇÇÈÇ±ÇÇTMñæÇÁÇ©Ç...Ç»ÇËÇ<ÇµÇÅB
VAD
óñ@Ç®ÇÊÇ--
VAMP
óñ@Ç...ëoeê´ÇÃçúêë
ÅiÉtÉFÅ[ÉYÇPÅj
éÓÇ...å¯â ÇTMÇÇÈÇäë"ÇÇÍÇÇ¢ÇÈ
PSC883
ÇÅAï°êîÇÃó'èééå±Ç...Ç®Ç¢Çåüì¢ÇÇÍÇÇ¢
Ç<ÇÅBëççáìIÇ»ï]âøÇÕñæÇÁÇ©ÇÇÕÇ»Ç¢ÇÇÃÇÃÅA
VAD
Ç®ÇÊÇ--
VAMP
Ç...íÔçRê´ÇÃäé"ÇTM
ëÊáUëäééå±
ê>íËÇÇÍÇìäó^ó ÇÉXÉPÉWÉÖÅ[ÉãÇ...ÇÊÇÈóLå¯ê´ÇÃï]âøÇçsÇ§
îâûÇÇÈÇ±ÇÇTMîFÇflÇÁÇÍÇ<ÇµÇÅBÉAÉhÉäÉAÉ}ÉCÉVÉìÇÉäÉ|É]Å[ÉÄâªÇµÇ
Doxil
T M
ÇÇ¢
ÅiÉtÉFÅ[ÉYÇQÅj
Ç§âªäwóñ@ç<ÇìØólÇÃééå±ìóeÇåüì¢ÇÇÍÇÇ¢Ç<ÇÅB
Å¶ñÛíçÅFìñ{ÇçsÇ»ÇÌÇÍÇÉrÉmÉåÉãÉrÉìÇÃé°å±ÇÇÕÅAÇªÇÃóLå¯ê´ÇTMèÿñæÇÇ´Ç»Ç©Ç¡Ç
ëÊáVëäééå±
êVÇÇ»é°óñ@Çï]âøÇÇÈÇÇflÇ...ïWèÄìIÇ»é°óñ@ÇÇÃîärÇçsÇ§
ÅiÉtÉFÅ[ÉYÇRÅj
êï®äwìIñÚç<
ëÊáWëäééå± FDA
èîFå,,ÅAîÔópå¯â
Q ÅA
OL
Ç...ëOEÇÇÈâeãøÅAÇªÇÃÇYÇ©ÇÃîärå§
ÉxÅ[É^ÉVÉìÅi
Betathin
ÅjÇÉCÉìÉ^Å[ÉçÉCÉLÉìÇQÇ®ÇÊÇ--
12ÇÕè´óàóLñ]Ç»êï®äwìIñÚç<
ÅiÉtÉFÅ[ÉYÇSÅj
ãÜÇçsÇ§
ÇÇÇËÅAåªç>ó'èééå±ÇTMçsÇÌÇÍÇÇ¢Ç<ÇÅBëOó'èÇ®ÇÊÇ--ëOäó'èééå±Ç...Ç®Ç¢ÇÇªÇÃ
FDA: Food and Drug Association ÅiïÅjêHïià,,ñÚïiã«
óLå¯ê´ÇTMé¶ÇÇÍÇ<ÇµÇÅB
à/êAóñ@
çúêëÇ<ÇÇÕññèååë¢ååäçñEà/êAÇîÇ§ëÂó óñ@ÇÃé°óê¨â Çâ¸ëPÇÇÈÇÇflÇ...ÅAë
30
31

éQçlïå£
àÍî èÓïÒ
ibDunitz M. Myeloma ÅiMehta J, Singhal S, edsÅj. Taylor and Francis Group, 2002: 1-901865-
50-9.
ibBataille R, Harousseau JL. Multiple myeloma. New England Journal of Medicine. 1997; 336:
1657-1664.
çúêëéÓÇÃóéj
ibKyle RA. History of multiple myeloma. In: Neoplastic Diseases of the Blood, 3rd edition.
ÅiWiernik PH, Canellos GP, Kyle RA, Schiffer CA, edsÅj. New York: Churchill Livingstone,
1996.
ibKyle RA. History of multiple myeloma. In: Neoplastic Diseases of the Blood, 2nd edition.
ÅiWiernik PH, Canellos GP, Kyle RA, Schiffer CA, edsÅj. New York: Churchill Livingstone,
1991: 325-32.
çúêëéÓÇÃâuäw
ibJemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52:
23-47.
ibSchwartz GG. Multiple myeloma: clusters, clues, and dioxins. Cancer Epidemiol Biomarkers
Prev. 1997; 6: 49-56.
ibSchottenfeld D, Fraumeni JF
edsJr.
Åj. Åi
Cancer Epidemiology and Prevention, 2nd edn.
New York: Oxford University Press; 1996: 946-970.
ibHerrington LJ, Weiss NS, Olshan AF. The epidemiology of myeloma. In: Myeloma Biology
and Management ÅiMalpas JS, Bergsagel DE, Kyle RA eds.Åj. Oxford, England, Oxford
University Press: 1995: 127-168.
çúè«èÛ
ibRosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment
of skeletal metastases in patients with breast cancer or osteolyticc lesions of multiple
myeloma: a phase III, double blind, comparative trial. Cancer J. 2001; 7: 377-387.
ibMajor P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia
of malignancy: a pooled analysis of two randomised, controlled clinical trials. Journal of
Clinical Oncology. 2001; 19, 558-67.
ibBerenson J, et al. Long-term pamidronate treatment of advanced multiple myeloma reduces
skeletal events. Journal of Clinical Oncology. 1998; 16: 593-602.
ibMcCloskey EV, et al. A randomised trial of the effect of clodronate on skeletal morbidity in
multiple myeloma. British Journal of Haematology. 1998; 100: 317-25.
ibMundy GR, Yoneda T. Bisphosphonates as anticancer drugs. New England Journal of
Medicine. 1998; 339: 398-400.
ibBerenson J, et al. Efficacy of pamidronate in reducing skeletal events in patients with
advanced multiple myeloma. New England Journal of Medicine. 1996; 334: 488-493.
ibBataille R, et al. Mechanism of bone destruction in multiple myeloma. The importance of an
unbalanced process in determining the severity of lytic bone disease. Journal of Clinical
Oncology. 1989; 7: 1909.
ibDurie BGM, Salmon SE, Mundy GR. Relation of osteoclast activating factor production to
32
33

ibAlexanian R, Dimopoulus M. The treatment of multiple myeloma. New England Journal of
Medicine 1994; 330: 484-9.
ibBuzaid AC, Durie BGM. Management of refractory myeloma ? a review. Journal of Clinical
Oncology 1988; 6: 889-905.
ÉTÉCÉgÉJÉCÉìóñ@
ibBlade J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple
myeloma: benefit for a small proportion of patients? Med Oncology. 2000; 77-84.
ibMandelli F, et al. Maintenance treatment with alpha-2b recombinant interferon significantly
improves response and survival duration in multiple myeloma patients responding to
conventional induction chemotherapy. Results of an Italian randomized study. New England
Journal of Medicine. 1990; 322: 1430.
ibLudwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with
multiple myeloma. New England Journal of Medicine 1990; 322: 1693-9.
ibMusto P, et al. Clinical results of recombinant erythropoietin in transfusion-dependent
patients with refractory multiple myeloma: role of cytokines and monitoring of
erythropoiesis. European Journal of Haematology. 1997; 58: 314-19.
é©âà/êA
ibMartinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or
autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of
Clinical Oncology. 2000; 18: 2273-81.
ibDesikau KR, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1000 patients with
multiple myeloma: durable complete remissions and superior survival in the absence of
chromosome 13 abnormalities. Blood. 2000; 95: 4008-4010.
ibBarlogie B, Jagannath S, Desikau KR, et al. Total therapy with tandem transplants for newly
diagnosed multiple myeloma. Blood. 1999; 93: 55-65.
ibCunningham D, et al. A randomized trial of maintenance interferon following high-dose
chemotherapy in multiple myeloma: long-term follow-up results. British Journal of
Haematology. 1998; 102: 495-502.
ibMehta J, Powles RL. Autologous blood and marrow transplantation. In: Leukaemia and
Associated Diseases. ÅiWhittaker JA, Holmes JA, edsÅj. Oxford: Blackwell Science, 1998;
455-81.
ibFermaud JP, Ravaud P, Chevert S, et al. High dose therapy and autologous peripheral blood
stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a
multicenter sequential randomized clinical trial. Blood. 1998; 92: 3131-3136.
ibAttal M, Harousseau JL, Stoppa A-M, et al. A prospective, randomized trial of autologous
bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal
of Medicine. 1996; 335: 91-97.
ibGore ME, Viner C, Meldrum M. Intensive treatment of multiple myeloma and criteria for
complete remission. Lancet. 1989; 14: 879.
ibMcElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and
myeloma. Lancet. 1983; 2: 822.
ìØånà/êAÅAìØéÌà/êA
ibMaloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogeneic graft-vs-
myeloma effect with high dose autologous stem cell rescue in the treatment of multiple
34
35

Published by the International Myeloma Foundation (IMF)
Åg Until There is a Cure... There is the IMF.Åh
International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421 USA
Hotline (USA and Canada): (800) 452-CURE
Telephone: (818) 487-7455
Facsimile: (818) 487-7454
E-Mail: TheIMF@myeloma.org
Website: www.myeloma.org
ìåãûòAóçéññ±èä
okuboikumi@nifty.com
2003, International Myeloma Foundation
Dedicated to improving the quality of life of myeloma patients
while working toward prevention and a cure.